Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/004655

International filing date: 11 February 2005 (11.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/623,021
Filing date: 27 October 2004 (27.10.2004)

Date of receipt at the International Bureau: 11 March 2005 (11.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



129402

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 02, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: ***60/623,021***
FILING DATE: ***October 27, 2004***
RELATED PCT APPLICATION NUMBER: ***PCT/US05/04655***

UNITED STATES PATENT AND TRADEMARK OFFICE
DEPARTMENT OF COMMERCE

Certified by

Jon W. Dudas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PTO/SB/16 (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No. EV471075440US

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Valentina	Molteni	San Diego, California
Xiaolin	Li	Del Mar, California

Additional inventors are being named on the _____ separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS

Direct all correspondence to: **CORRESPONDENCE ADDRESS**

☒ The address corresponding to Customer Number: **29490**

OR

☐ Firm or Individual Name

Address

City	State	Zip
Country	Telephone	Fax

ENCLOSED APPLICATION PARTS *(check all that apply)*

☒ Specification *Number of Pages* 64 ☐ CD(s), Number ____

☐ Drawing(s) *Number of Sheets* ____ ☐ Other (specify) ____

☒ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☐ Applicant claims small entity status. See 37 CFR 1.27.

☐ A check or money order is enclosed to cover the filing fees

☐ Payment by credit card. Form PTO-2038 is attached.

FILING FEE Amount($): 160

☒ The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 50-1885
A duplicative copy of this form is enclosed for fee processing.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: ____.

[Page 1 of 2]

Respectfully submitted,
SIGNATURE

Date October 27, 2004

TYPED or PRINTED NAME Scott W. Reid, D. Phil.

REGISTRATION NO. *(if appropriate)* 48,097

TELEPHONE 858-812-1796

Docket Number: P1165US00

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

PROVISIONAL APPLICATION COVER SHEET
Additional Page

First Named Inventor	MOLTENI, Valentina	Docket Number P1165US00

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Juliet	Nabakka	San Diego, California
David Archer	Ellis	San Diego, California
Beth Marie	Anaclerio	San Diego, California
John	Wityak	Carlsbad, California
Enrique	Saez	San Diego, California

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-.

Docket No.: P1165US00
Express Mail Label No.: EV471075440US

United States Provisional Patent Application

COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS

Inventors: MOLTENI, Valentina, a citizen of Italy,
residing at 2475 E Street, San Diego, California 92102
LI, Xiaolin, a citizen of People's Republic of China,
residing at 14059-G Mango Drive, Del Mar, California 92014
NABAKKA, Juliet, a citizen of United States of America,
residing at 6120 Decena Drive #105, San Diego, California 92120
ELLIS, David Archer, a citizen of United States of America,
residing at 1631 State Street, #2, San Diego, California 92101
ANACLERIO, Beth Marie, a citizen of United States of America,
residing at 10721 Ballystock Court, San Diego, California 92130
WITYAK, John, a citizen of United States of America,
residing at 3377 Avenida Nieve, Carlsbad, California
SAEZ, Enrique, having dual citizenship in Spain and United States of America, residing at 1547 1/2 Felspar Street, San Diego, California 92109

AS FILED IN USPTO ON OCTOBER 27, 2004

Assignee: IRM LLC, a Delaware Limited Liability Company
P.O. Box HM 2899
Hamilton HM LX, BERMUDA

Entity: Large

Genomics Institute of the
Novartis Research
Foundation

Scott W. Reid, Reg. No. 48,097
10675 John Jay Hopkins Drive
San Diego, CA 92121
Tel 858 812-1796
Fax 858 812-1981
sreid@gnf.org

COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS

BACKGROUND OF THE INVENTION

Field of the Invention

[0001] The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

Background

[0002] Liver X receptors (LXRs), LXRα and LXRβ, are nuclear receptors that regulate the metabolism of several important lipids, including cholesterol and bile acids. While LXRβ is expressed ubiquitously in the body, LXRα is expressed in the liver and to a smaller degree in the kidneys, small intestine, adipose tissue, spleen and adrenal glands.

[0003] LXRs bind to the ATP binding cassette transporter-1 (ABCA1) promoter and increase expression of the gene to produce ABCA1 protein. ABCA1 is a membrane bound transport protein that is involved in the regulation of cholesterol efflux from extra-hepatic cells onto nascent high-density lipoprotein (HDL) particles. Mutations in the ABCA1 gene result in low levels of HDL and an accompanying increased risk of cardiovascular diseases such as atherosclerosis, myocardial infarction and ischemic stroke. LXRα and β agonists have been shown to increase ABCA1 gene expression thereby increasing HDL cholesterol and, as a consequence, decreasing both the net absorption of cholesterol and the risk of cardiovascular disease. LXR agonists also upregulate macrophage expression of apolipoprotein E (apoE) and ABCG1, both of which contribute to the efflux of cellular cholesterol. By stimulating macrophage cholesterol efflux through upregulation of ABCA1, ABCG1 and/or apoE expression, as well as increasing the expression of other target genes including cholesterol ester transfer protein and lipoprotein lipase, LXR agonists influence plasma lipoproteins.

[0004] The novel compounds of this invention modulate the activity of LXRs and are, therefore, expected to be useful in the treatment of LXR-associated diseases such as cardiovascular diseases, inflammation and disorders of glucose metabolism such as insulin resistance and obesity.

SUMMARY OF THE INVENTION

[0005] In one aspect, the present invention provides compounds of Formula I:



in which

n is selected from 0, 1, 2 and 3;

Z is selected from C and S(O); each

Y is independently selected from $-CR_4=$ and $-N=$; wherein R_4 is selected from hydrogen, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

R_1 is selected from halo, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy and $-C(O)OR_4$; wherein R_4 is as described above;

R_2 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_2 is optionally substituted with 1 to 5 radicals independently selected from halo, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-C(O)NR_5R_5$, $-OR_5$, $-OC(O)R_5$, $-NR_5R_6$, $-C(O)R_5$ and $-NR_5C(O)R_5$; wherein R_5 and R_6 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, C_{6-10}aryl-C_{0-4}alkyl, C_{3-8}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-}

$_4$alkyl; or R_5 and R_6 together with the nitrogen atom to which R_5 and R_6 are attached form C_{5-10}heteroaryl or C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_5 or the combination of R_5 and R_6 is optionally substituted with 1 to 4 radicals independently selected from halo, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

[0006] R_3 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_3 is substituted with 1 to 5 radicals independently selected from halo, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, -OXR_7, -$OXC(O)NR_7R_8$, -$OXC(O)NR_7XC(O)OR_8$, -$OXC(O)NR_7XOR_8$, -$OXC(O)NR_7XNR_7R_8$, -$OXC(O)NR_7XS(O)_{0-2}R_8$, -$OXC(O)NR_7XNR_7C(O)R_8$, -$OXC(O)NR_7XC(O)XC(O)OR_8$, -$OXC(O)NR_7R_9$, -$OXC(O)OR_7$, -$OXOR_7$, -OXR_9, -XR_9, -$OXC(O)R_9$, -$OXS(O)_{0-2}R_9$ and -$OXC(O)NR_7CR_7[C(O)R_8]_2$;wherein X is a selected from a bond and C_{1-6}alkylene wherein any methylene of X can optionally be replaced with a divalent radical selected from C(O), NR_7, $S(O)_2$ and O; R_7 and R_8 are independently selected from hydrogen, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{2-6}alkenyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; R_9 is selected from C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-4}alkyl; wherein any alkyl of R_9 can have a hydrogen replaced with –$C(O)OR_{10}$; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from halo, C_{1-6}alkyl, C_{3-12}cycloalkyl, halo-substituted-C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkoxy, -$XC(O)OR_{10}$, -$XC(O)R_{10}$, -$XC(O)NR_{10}R_{10}$, -$XS(O)_{0-2}NR_{10}R_{10}$ and -$XS(O)_{0-2}R_{10}$; wherein R_{10} is independently selected from hydrogen and C_{1-6}alkyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds.

[0007] In a second aspect, the present invention provides a pharmaceutical composition which contains a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof; or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.

[0008] In a third aspect, the present invention provides a method of treating a disease in an animal in which modulation of LXR activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof.

[0009] In a fourth aspect, the present invention provides the use of a compound of Formula I in the manufacture of a medicament for treating a disease in an animal in which LXR activity contributes to the pathology and/or symptomology of the disease.

[0010] In a fifth aspect, the present invention provides a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof, and the pharmaceutically acceptable salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0011] "Alkyl" as a group and as a structural element of other groups, for example halo-substituted-alkyl and alkoxy, can be either straight-chained or branched. C_{1-6}alkoxy includes, methoxy, ethoxy, and the like. Halo-substituted alkyl includes trifluoromethyl, pentafluoroethyl, and the like.

[0012] "Aryl" means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms. For example, aryl can be phenyl or naphthyl, preferably phenyl. "Arylene" means a divalent radical derived from an aryl group. "Heteroaryl" is as defined for aryl where one or more of the ring members are a heteroatom. For example heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[1,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl, etc. "$C_{6-10}arylC_{0-4}alkyl$" means an aryl as described above connected via a alkylene grouping. For example, $C_{6-10}arylC_{0-4}alkyl$ includes phenethyl, benzyl, etc.

[0013] "Cycloalkyl" means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated. For example, C_{3-10}cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. "Heterocycloalkyl" means cycloalkyl, as defined in this application, provided that one or more of the ring carbons indicated, are replaced by a moiety selected from -O-, -N=, -NR-, -C(O) -, -S-, -S(O) - or -$S(O)_2$-, wherein R is hydrogen, C_{1-4}alkyl or a nitrogen protecting group. For example, C_{3-8}heterocycloalkyl as used in this application to describe compounds of the invention includes morpholino, pyrrolidinyl, piperazinyl, piperidinyl, piperidinylone, 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, etc.

[0014] "Halogen" (or halo) preferably represents chloro or fluoro, but can also be bromo or iodo.

[0015] The term "modulate" with respect to an LXR receptor refers to activation of the LXR receptor and its biological activities associated with the LXR pathway (e.g., transcription regulation of a target gene). Modulation of LXR receptor can be up-regulation (i.e., agonizing, activation or stimulation) or down-regulation (i.e. antagonizing, inhibition or suppression). The mode of action of an LXR modulator can be direct, e.g., through binding to the LXR receptor as a ligand. The modulation can also be indirect, e.g., through binding to and/or modifying another molecule which otherwise binds to and activates the LXR receptor, or by stimulating the generation of an endogenous LXR ligand. Thus, modulation of LXR includes a change in the bioactivities of an LXR agonist ligand (i.e., its activity in binding to and/or activating an LXR receptor) or a change in the cellular level of the ligand.

[0016] "Treat", "treating" and "treatment" refer to a method of alleviating or abating a disease and/or its attendant symptoms.

Description of the Preferred Embodiments

[0017] The present invention provides compounds, compositions and methods for the treatment of diseases in which modulation of LXR activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the

diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I.

[0018] In one embodiment, compounds of the invention are of Formula Ia:



in which

n is selected from 1, 2 and 3;

Y is selected from –CH= and –N=;

R_1 is selected from halo, C_{1-6}alkyl, and –C(O)OR_4; wherein R_4 is selected from hydrogen and C_{1-6}alkyl;

R_2 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_2 is optionally substituted with 1 to 4 radicals independently selected from halo, hydroxy, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl and –OC(O)R_5; wherein R_5 is selected from hydrogen and C_{1-6}alkyl; and

R_3 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_3 is substituted with 1 to 5 radicals independently selected from halo, hydroxyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, -OXR_7, -OXC(O)NR_7R_8, -OXC(O)$NR_7XC(O)OR_8$, -OXC(O)NR_7XOR_8, -OXC(O)$NR_7XNR_7R_8$, -OXC(O)$NR_7XS(O)_{0-2}R_8$, -OXC(O)$NR_7XNR_7C(O)R_8$, -OXC(O)$NR_7XC(O)XC(O)OR_8$, -OXC(O)NR_7R_9, -OXC(O)OR_7, -$OXOR_7$, -OXR_9, -XR_9, -OXC(O)R_9 and -OXC(O)$NR_7CR_7[C(O)R_8]_2$;wherein X is a selected from a bond and C_{1-6}alkylene; R_7 and R_8 are independently selected from hydrogen, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{2-6}alkenyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; R_9 is selected from C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-4}alkyl; wherein any alkyl of R_9 can have a hydrogen replaced with

–C(O)OR_{10}; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from halo, C_{1-6}alkyl, C_{3-12}cycloalkyl, halo-substituted-C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkoxy, -XC(O)OR_{10}, -XC(O)R_{10}, -XC(O)$NR_{10}R_{10}$, -XS(O)$_{0-2}NR_{10}R_{10}$ and -XS(O)$_{0-2}R_{10}$; wherein R_{10} is independently selected from hydrogen and C_{1-6}alkyl.

[0019] In another embodiment, R_1 is selected from fluoro, chloro, methyl and -C(O)OCH_3; and R_2 is selected from the group consisting of phenyl, cyclohexyl, cyclopentyl and pyridinyl; wherein any aryl, heteroaryl or cycloalkyl of R_2 is optionally substituted with 1 to 4 radicals independently selected from fluoro, chloro, bromo, hydroxy, methyl, methoxy, trifluoromethyl and -OC(O)CH_3.

[0020] In another embodiment, R_3 is selected from the group consisting of phenyl, benzo[1,3]dioxolyl, pyridinyl and benzooxazolyl; wherein any aryl or heteroaryl of R_3 is substituted with 1 to 5 radicals independently selected from fluoro, chloro, bromo, methoxy, hydroxyl, difluoromethoxy, -$OCH_2C(O)NH_2$, -$OCH_2C(O)OCH_3$, -$OCH_2C(O)NHCH_3$, -$OCH_2C(O)N(CH_3)_2$, -R_9, -OR_9, -OCH_2R_9, -$OCH_2C(O)R_9$, -$OCH_2C(O)NHR_9$, -$OCH_2C(O)N(CH_3)R_9$, -OCH_2CN, -$OCH_2C_2H_3$, -$OCH_2C_2H_4$, -$O(CH_2)_2OH$, -$OCH_2C(O)NH(CH_2)_2C(O)OC_2H_5$, -$OCH_2C(O)NH(CH_2)_2CH_2F$, -$OCH_2C(O)NH(CH_2)_2C(O)OH$, -$OCH_2C(O)NHC(O)(CH_2)_2C(O)OCH_3$, -$OCH_2C(O)NH(CH_2)_2NHC(O)CH_3$, -$OCH_2C(O)NHCH_2C(O)C_2H_5$, -$OCH_2C(O)NH(CH_2)_2C(O)OC_4H_9$, -$OCH_2C(O)NHCH_2C(O)OC_2H_5$, -$OCH_2C(O)NHCH[C(O)OC_2H_5]_2$, -$S(O)_2CH_3$, -$OCH_2C(O)NHCH_2CF_3$, -$OCH_2C(O)NHCH_2C(O)(CH_2)_2C(O)OCH_3$, -$OCH_2C(O)N(CH_3)CH_2C(O)OCH_3$, -$OCH_2C(O)NH(CH_2)_3OC_2H_5$, -$OCH_2C(O)NH(CH_2)_3OCH(CH_3)_2$, -$OCH_2C(O)NH(CH_2)_2SCH_3$, -$OCH_2C(O)NHCH_2CH(CH_3)_2$, -$OCH_2C(O)NHCH_2CH(CH_3)C_2H_5$, -$OCH_2C(O)NHCH(CH_3)C(O)OC_2H_5$, -$OCH_2C(O)NHCH_2CH(CH_3)_2$ and -$OCH_2C(O)(CH_2)_3OCH(CH_3)_2$; wherein R_9 is phenyl, cyclopropyl-methyl, isoxazolyl, benzthiazolyl, furanyl, furanyl-methyl, pyridinyl, 4-oxo-4,5-dihydro-thiazol-2-yl, pyrazolyl, isothiazolyl, 1,3,4-thiadiazolyl, thiazolyl, phenethyl, morpholino, morpholino-propyl, isoxazolyl-methyl, pyrimidinyl, tetrahydro-pyranyl, 2-oxo-2,3-dihydro-pyrimidin-4-yl, piperazinyl, pyrrolyl, piperidinyl, pyrazinyl, imidazolyl, imidazolyl-propyl, benzo[1,3]dioxolyl, benzo[1,3]dioxolyl-propyl, 2-oxo-pyrrolidin-1-yl

and 2-oxo-pyrrolidin-1-yl-propyl; wherein any alkyl of R_9 can have a hydrogen replaced with $-C(O)OC_2H_5$; wherein any aryl, heteroaryl or heterocycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from methyl, ethyl, cyclopropyl, methoxy, trifluoromethyl, $-OC(O)CH_3$, -COOH, $-CH_2C(O)OH$, $-CH_2C(O)OC_2H_5$, $-CH_2C(O)OCH_3$, $-C(O)OCH_3$, $-C(O)NH_2$, $-C(O)NHCH_3$ and $-C(O)CH_3$.

[0021] Preferred compounds of Formula I are detailed in the Examples and Table I, *infra*.

Pharmacology and Utility

[0022] Compounds of the invention modulate the activity of LXRs and, as such, are useful for treating diseases or disorders in which LXRs contribute to the pathology and/or symptomology of the disease. This invention further provides compounds of this invention for use in the preparation of medicaments for the treatment of diseases or disorders in which LXRs contribute to the pathology and/or symptomology of the disease. LXR mediated diseases or conditions include inflammation, cardiovascular disease including atherosclerosis, arteriosclerosis, hypercholesteremia, hyperlipidemia and disorders of glucose homeostasis, including insulin resistance, type II diabetes, and obesity.

[0023] Lipoprotein metabolism is a dynamic process comprised of the production of triglyceride and cholesterol rich particles from the liver as very low-density lipoprotein (VLDL), modification of these lipoprotein particles within the plasma (VLDL to intermediate density (IDL) to low-density lipoprotein (LDL)) and clearance of the particles from the plasma, again by the liver. This process provides the transport of triglycerides and free cholesterol to cells of the body. Reverse cholesterol transport is the proposed mechanism by which excess cholesterol is returned to the liver from extra-hepatic tissue.

[0024] The process is carried out by high-density lipoprotein (HDL) cholesterol. The combination of lipoprotein production (VLDL, HDL) from the liver, modification of particles (all) within the plasma and subsequent clearance back to the liver, accounts for the steady state cholesterol concentration in plasma. Compounds of this invention increase reverse cholesterol transport by increasing cholesterol efflux from the arteries.

This invention includes the use of compounds of this invention for the preparation of a medicament for increasing reverse cholesterol transport. Additionally, this invention provides compounds for inhibiting cholesterol absorption and the use of compounds of this invention for the preparation of a medicament for inhibiting net cholesterol absorption.

[0025] The compounds of this invention can also be useful for the prevention or treatment of inflammation and neurodegenerative diseases or neurological disorders. Accordingly, this invention also provides a method for preventing or treating inflammation and a method for preventing or treating neurodegenerative diseases or neurological disorders, particularly neurodegenerative diseases or disorders characterized by neuron degeneration, neuron injury or impaired plasticity or inflammation in the CNS. Particular diseases or conditions that are characterized by neuron degeneration and inflammation and thus benefiting from the growth and/or repair of neurons include stroke, Alzheimer's disease, fronto-temporal dementias (tauopathies); peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis. Diseases or conditions that are characterized by neuron degeneration and/or impaired plasticity include psychiatric disorders such as schizophrenia and depression. Particular diseases or conditions that are characterized by neuronal injury include those conditions associated with brain and/or spinal cord injury, including trauma. In addition, the compounds of this invention can be used to treat or prevent various diseases with an inflammatory component, such as rheumatoid arthritis, osteoarthritis, psoriasis, asthma, etc.

[0026] LXR agonists improve glucose tolerance and enhance glut4 expression (U.S. Provisional Patent Application 60/436,112, filed 12/23/2002; U. S. Patent Application 10/745,334, filed 12/22/2003). There is a coordinated regulation of genes involved in glucose metabolism in liver and adipose tissue. In the liver, LXR agonists inhibit expression of several genes that are important for hepatic gluconeogenesis, e.g., PGC-1, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase expression. Inhibition of these gluconeogenic genes is accompanied by an induction in expression of glucokinase, which promotes hepatic glucose utilization. It was also found

that glut4 mRNA levels were upregulated by LXR agonists in adipose tissue, and that glucose uptake in 3T3-L1 adipocytes was enhanced in vitro.

[0027] In accordance with these discoveries, the present invention provides methods for enhancing glut4 expression in cells in a subject by administering a compound of the invention to the subject. The present invention also provides methods for treating diabetes mellitus and related disorders, such as obesity or hyperglycemia, by administering to a subject an effective amount of a compound of the invention to ameliorate the symptoms of the disease. For example, type II diabetes is amenable to treatment with methods of the present invention. By enhancing sensitivity to insulin and glucose uptake by cells, administration with a compound of the invention can also treat other diseases characterized by insulin dysfunction (e.g., resistance, inactivity or deficiency) and/or insufficient glucose transport into cells.

[0028] Compounds of the present invention also regulate expression levels of a number of genes that play important roles in liver gluconeogenesis. Accordingly, the present invention further provides methods for reducing gluconeogenesis in a subject by modulating expression of such genes (e.g., PGC-1 and PEPCK).

[0029] In accordance with the foregoing, the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount (*See, "Administration and Pharmaceutical Compositions", infra*) of a compound of Formula I or a pharmaceutically acceptable salt thereof. For any of the above uses, the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.

Administration and Pharmaceutical Compositions

[0030] In general, compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and

other factors. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5mg to about 100mg, conveniently administered, e.g. in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50mg active ingredient.

[0031] Compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrollidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions. The compositions can be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they can also contain other therapeutically valuable substances. Suitable formulations for transdermal applications include an effective amount of a compound of the present invention with a carrier. A carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally

with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Matrix transdermal formulations can also be used. Suitable formulations for topical application, e.g., to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[0032] Compounds of the invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations). For example, synergistic effects can occur with other substances used in the treatment of cardiovascular, inflammatory and/or neurodegenerative diseases. Examples of such compounds include fibrates, TZDs, metformin, etc. Where the compounds of the invention are administered in conjunction with other therapies, dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.

[0033] The invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration.

[0034] The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

[0035] The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time

limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.

Processes for Making Compounds of the Invention

[0036] The present invention also includes processes for the preparation of compounds of the invention. In the reactions described, it can be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.

[0037] Compounds of Formula I can be prepared by proceeding as in the following Reaction Scheme I:

Reactions Scheme I



in which n, Y, Z, R_1, R_2 and R_3 are as defined in the Summary of the Invention. Compounds of Formula I are prepared by reacting a compound of formula 2 with a compound of formula 3 to form a compound of formula 4 which is further reacted with a compound of formula 5 or 6. The entire reaction is carried out in the presence of a suitable solvent (e.g., dichloromethane, or the like) and a suitable base (e.g., DIEA, or the like). The reaction is carried out in the temperature range of about 5 to about 30°C and takes up to 20 hours to complete.

Additional Processes for Making Compounds of the Invention

[0038] A compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Alternatively, the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.

[0039] The free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively. For example a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).

[0040] Compounds of the invention in unoxidized form can be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.

[0041] Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et

al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).

[0042] Protected derivatives of the compounds of the invention can be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc., 1999.

[0043] Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

[0044] Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.

[0045] In summary, the compounds of Formula I can be made by a process, which involves:

(a) that of reaction scheme I; and

(b) optionally converting a compound of the invention into a pharmaceutically acceptable salt;

(c) optionally converting a salt form of a compound of the invention to a non-salt form;

(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;

(e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form;

(f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers;

(g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and

(h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.

[0046] Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter.

[0047] One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used.

Examples

[0048] The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds of Formula I according to the invention.

Example 1

5-(4-Chloro-phenyl)-2-(2-difluoromethoxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2-fluoro-

phenyl)-methanone



Preparation of 4-chloro-thiobenzoic acid hydrazide



[0049] One half of volume of a solution of KOH (1.06 mol) in 400 ml of EtOH is saturated with H_2S. This solution is recombined with the other half of the KOH solution and the resulting solution is stirred under N_2 at 45-50 °C before adding 4-chlorobenzotrichloride (0.25 mol) at a rate to keep the temperature at 50-60 °C (~ 1.5 hours). The deep red mixture is refluxed for 30 minutes, then treated with a solution of chloroacetic acid (0.35 mol) and $NaHCO_3$ (0.35 mol) in H_2O (200 mL). The reaction mixture is reheated under reflux for an additional 5 minutes. The resulting brownish-red solution is decanted from the sticky resin and acidified with concentrated HCl to pH = 1. The red solution on crystallization yields (4-chloro-thiobenzoylsulfanyl)-acetic acid: ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.75 (d, 2H), 7.15 (d, 2H), 4.04 (s, 2H).

[0050] To a mixture of (4-chloro-thiobenzoylsulfanyl)-acetic acid (8.31 mmol) in 9 mL of NaOH (1N) is added hydrazine hydrate (36.7 mL). Glacial acetic acid (2.7 mL) is then added to the solution and the mixture is vigorously stirred. The reaction mixture is diluted with CH_2Cl_2 and the organic layer dried over $MgSO_4$ to yield 4-chloro-thiobenzoic acid hydrazide: LC/MS (ES^+) 186.9 $(M+1)^+$.

To a heterogeneous mixture of 4-chloro-thiobenzoic acid hydrazide (0.107 mmol) in CH_2Cl_2 (1 mL) is added 2-difluoromethoxy-benzaldehyde (0.128 mmol) and DIEA (0.128 mmol). After 10 minutes the mixture become homogenous and the reaction is complete by TLC and LCMS to give 5-(4-chloro-phenyl)-2-(2-difluoromethoxy-phenyl)-

2,3-dihydro-[1,3,4]thiadiazole which is used in the next step without evaporation of the solvent.

[0051] To the solution of 5-(4-chloro-phenyl)-2-(2-difluoromethoxy-phenyl)-2,3-dihydro-[1,3,4]thiadiazole is added DIEA (0.16 mmol) and 2-fluorobenzoyl chloride (0.16 mmol) and the reaction mixture is stirred for 12 hours at room temperature. After evaporation of the solvent, the residue is purified by automated chromatography (hexane/EtOAc) to give 5-(4-chloro-phenyl)-2-(2-difluoromethoxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2-fluoro-phenyl)-methanone: ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.39-7.35 (m, 1H), 7.34-7.29 (m, 4H), 7.25 (dd, J_1 = 7.8 Hz, J_2 =1.2 Hz, 1H), 7.19-7.13 (m, 3H), 7.04 (m, 1H), 6.97 (m, 2H), 6.50 (dd, J_1 = 71.6 Hz, J_2 = 71.2Hz, 1H). LC/MS: (ES^+) 462.8 $(M+1)^+$.

Example 2

2-{2-[5-(4-Chloro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-acetamide



[0052] To a heterogeneous mixture of 4-chloro-thiobenzoic acid hydrazide (1.3 mmol) in 12 mL of CH_2Cl_2 is added 2-(2-formylphenoxy)acetamide (1.53 mmol) and DIEA (1.53 mmol). After 10 minutes the mixture become homogenous and the reaction is complete by TLC and LCMS to give 2-(2-(5-(4-chlorophenyl)-2,3-dihydro-1,3,4-thiadiazol-2-yl)phenoxy)-acetamide which is used as such in the next step without evaporation of the solvent.

[0053] To the solution of 2-(2-(5-(4-chlorophenyl)-2,3-dihydro-1,3,4-thiadiazol-2-yl)phenoxy)acetamide is added DIEA (2.0 mmol) and 2,4,6-tri-fluorobenzoyl chloride (2.0 mmol) and the reaction mixture is stirred for 12 hours at room temperature. After evaporation of the solvent, the residue is purified by automated chromatography (hexane/EtOAc) to give 2-{2-[5-(4-chloro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-acetamide: ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.43 (s, 1H), 7.27 (d, J = 8.8, 2H), 7.15 (m, 2H), 7.14 (d, J = 8.4 Hz, 2H) 6.99 (bs, 1H), 6.84 (t, J = 6.4 Hz, 3H), 6.66 (d, J = 8.4 Hz, 1H), 6.53 (t, J = 8.0 Hz, 2H), 5.29 (bs, 1H), 4.47 (d, J = 1.6 Hz, 2H); LC/MS: (ES^+) 506.2 $(M+1)^+$.

Example 3

2-{2-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-6-methoxy-phenoxy}-acetamide



Preparation of 4-fluorobenzothiohydrazide trifluoroacetic acid salt or hydrochloride salt



HX

[0054] To a solution of 4-fluorobenzoic acid (35.7 mmol) in 72 mL of a mixture of DMF and THF (1:1), is added *tert*-butyl carbazate (37.5 mmol), EDC (39.3 mmol) and N,N-dimethylaminopyridine (0.54 mmol). After 10 minutes the mixture becomes homogeneous and stirring is continued for 3 hours until the reaction is complete by TLC and LC/MS. The reaction mixture is poured into ice. Upon addition of diethylether the organic layer is

separated. The organic layer is washed with sodium bisulfite, saturated sodium bicarbonate and saturated sodium chloride solution , dried over magnesium sulfate and concentrated to yield N'-(4-fluoro-benzoyl)-hydrazinecarboxylic acid *tert*-butyl ester: MS: (ES^+) 255 $(M+1)^+$.

[0055] To a mixture of N'-(4-fluoro-benzoyl)-hydrazinecarboxylic acid *tert*-butyl ester (11.1 mmol) in 10 mL of dry THF is added Lawesson's reagent (11.6 mmol) and the mixture is heated in the microwave oven at 80 °C for 20 minutes The reaction mixture is concentrated and purified by automated column chromatography using hexanes/EtOAc: ^1H NMR (400 MHz, $CDCl_3$) δ 9.8 (bs, 1H), 9.05 (bs, 1H); 8.0-7.97 (m, 2H), 7.31 (t, J = 8.4Hz, 2H), 1.73 (s, 9H). LC/MS: (ES^+) 271 $(M+1)^+$.

[0056] **Trifluoroacetic salt.** To a solution of N'-(4-fluoro-thiobenzoyl)-hydrazinecarboxylic acid *tert*-butyl ester (1.97 mmol) in CH_2Cl_2 is added trifluoroacetic acid (3 mL) and thioanisole (2.7 mmol). The mixture is stirred at room temperature for 1 hour. After evaporation of the solvent the mixture is purified by automated column chromatography (hexanes/EtOAc) to yield 4-fluoro-thiobenzoic acid hydrazide trifluoroacetic acid salt: ^1H NMR (400 MHz, $CDCl_3$) δ 9.5 (bs, 3H), 7.8-7.76 (m, 2H), 7.05 (t, J = 8.4 Hz, 2H); LC/MS: (ES^+) 171 $(M+1)^+$.

[0057] **Hydrochloride salt.** To N'-(4-fluoro-thiobenzoyl)-hydrazinecarboxylic acid *tert*-butyl ester (18.5 mmol) is added HCl (4 N) in 1,4-dioxane (185 mmol). The mixture is stirred at room temperature for 1 hour. Hexanes is added to further precipitate the product. The product is filtered off yielding 4-fluoro-thiobenzoic acid hydrazide hydrochloride salt: ^1H NMR (400 MHz, CH_3OD) δ 7.8 – 7.75 (m, 2H), 7.09 (t, J = 11.6 Hz, 2H). LC/MS: (ES^+) 171 $(M+1)^+$.

Preparation of 3-methoxy-2-triisopropylsilanyloxy-benzaldehyde



[0058] *O*-vanillin (26.3 mmol) is mixed with TIPSCl (39.6 mmol) and imidazole (78.7 mmol) in a microwave vessel. The mixture is heated in the microwave at 100 °C for 3

minutes. The oily mixture is diluted with EtOAc (100 mL) and washed with $NaHSO_4$ (1 M) (2x50 mL) and brine (50 mL). After drying with $MgSO_4$, the filtrate is concentrated. The resultant crude mixture is purified by silica flash chromatography (2% EtOAc/hexane) to yield 3-methoxy-2-triisopropylsilanyloxy-benzaldehyde as an oil: ^{1}H NMR (400 MHz, $CDCl_3$) δ 10.6 (s, 1H), 7.38 (dd, J_1 = 1.6 Hz, J_2 = 8 Hz, 1H), 7.04 (dd, J_1 = 1.6 Hz, J_2 = 8 Hz, 1H), 6.93 (td, J_1 = 8 Hz, J_2 = 0.8 Hz, 1H), 3.82 (s, 3H), 1.34-1,25 (m, 3H), 1.1 (s, 18H); LC/MS (ES^+): 309 $(M+1)^+$.

[0059] To a heterogeneous mixture of 4-fluoro-thiobenzoic acid hydrazide salt (2.06 mmol) in 8 mL of CH_2Cl_2 is added 3-methoxy-2-triisopropylsilanyloxy-benzaldehyde (2.27 mmol) and DIEA (4.13 mmol). After 15 minutes the mixture becomes homogenous and the reaction is complete by TLC and LCMS to give 5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-2,3-dihydro-[1,3,4]thiadiazole which is used in the next step without evaporation of the solvent.

[0060] To the solution of 5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-2,3-dihydro-[1,3,4]thiadiazole is added DIEA (3.09 mmol) and 2,4,6-trifluorobenzoyl chloride (3.09 mmol) and the reaction mixture is stirred for 12 hours at room temperature. After concentration, the residue is purified by automated column chromatography (hexane/EtOAc) to yield [5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone.

[0061] To [5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (32.3 µmol) is added tetrabutylammonium fluoride in tetrahydrofuran (1 M) (48.5 µmol). The mixture is stirred for an hour and 2-bromo-acetamide (48.5 µmol) is added. The mixture is stirred at room temperature for 12 hours. After evaporation of the solvent the residue is purified by preparative LC/MS (20-100 % MeCN/H_2O) to give 2-{2-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-6-methoxy-phenoxy}-acetamide: ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.63-7.62 (m, 2H), 7.57 (s, 1H), 7.22-7.12 (m, 3H), 7.02 (dd, J_1 = 8.4Hz, J_2 = 2Hz, 2H), 6.9 (bs, 1H), 6.85 (t, J = 8.4Hz, 2H), 6.10 (s, 1H), 4.83 (d, J = 15.2 Hz, 1H), 4.68 (d, J = 15.2 Hz, 1H), 3.94 (s, 3H).

Example 4

3-{3-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-

yl]-2-methoxy-phenoxymethyl}-benzoic acid methyl ester



Preparation of 2-Methoxy-3-triisopropylsilanyloxy-benzaldehyde



[0062] Guaiacol (2-methoxy-phenol, 34.6 mmol) is mixed with TIPSCl (51.9 mmol) and imidazole (103.8 mmol) in a tube. The mixture is heated in the microwave oven at 180 °C for 3 minutes. The oily mixture is diluted with EtOAc (100 mL) and washed with $NaHSO_4$ (1 M) (2x50 mL) and brine (50 mL). After drying over anhydrous Na_2SO_4, the filtrate is concentrated. The resultant crude mixture is purified by silica flash chromatography (2 % EtOAc/hexane) to yield triisopropyl-(2-methoxy-phenoxy)-silane as a colorless oil. Yield: 69%. ^1H NMR (400 MHz, $CDCl_3$) δ 6.8-6.89 (m, 4H), 3.8 (s, 3H), 1.22-1.28 (m, 3H), 1.1 (s, 9H), 1.08 (s, 9H). LC/MS (ES^+): (M+1), 281.2. R_f = 0.8 (5 % EtOAc/hexane). (Note: Alternatively, conventional heating might be adopted in which case NMP is the solvent of choice).

[0063] nBuLi (2.5 M in hexanes) (36 mmol) is mixed with TMEDA (36 mmol) at 0 °C in a dry round bottom flask for 10 minutes. A solution of triisopropyl-(2-methoxy-phenoxy)-silane (24 mmol) in 25 mL of dry THF is added to the above mixture. The mixture

is warmed up to room temperature in 2 hours by removal of the ice bath. The slightly yellow solution is then transferred to another dry flask containing dry 7.5 mL of DMF at room temperature. The mixture is stirred overnight. HCl (1 M) is added to the mixture to quench the reaction. The mixture is diluted with EtOAc (100 mL), washed with HCl (1 M) (2X100 mL) and brine (50 mL) and finally dried over anhydrous Na_2SO_4. Purification is accomplished by silica flash chromatography (5 % EtOAc/hexane) to yield 3-methoxy-2-triisopropylsilanyloxy-benzaldehyde as a colorless oil which needs to be stored at low temperatures: ^{1}H NMR (400 MHz, $CDCl_3$) δ 10.4 (s, 1H), 7.42 (dd, J_1 = 7.7 Hz, J_2 = 1.7 Hz, 1H), 7.67 (d, J_1 = 8 Hz, J_2 = 1.7 Hz, 1H), 7.04 (t, J = 8.4 Hz, 1H), 3.96 (s, 3H), 1.26-1.35 (m, 3H), 1.13 (s, 9H), 1.12 (s, 9H). LC/MS (ES^+): (M+1) 309.2. R_f = 0.4 (5 % EtOAc/hexane).

[0064] N'-(4-fluoro-thiobenzoyl)-hydrazinecarboxylic acid *tert*-butyl ester (1.23 mmol) is dissolved in 5 mL of CH_2Cl_2 at room temperature in a dry round bottom flask. Removal of the ester group is accomplished adding TFA (2 mL) to the solution at room temperature. The reaction is complete after 30 minutes as determined by LC/MS. Solvent is removed in vacuo. The resultant oil is dried on the vacuum line for 30 minutes and dissolved in 1 mL of dry CH_2Cl_2. This solution is added to a mixture of 3-methoxy-2-triisopropylsilanyloxy-benzaldehyde (1.23 mmol) and DIEA (4.9 mmol) in 1 mL of dry CH_2Cl_2. The mixture is allowed to stand at room temperature in the presence of molecular sieves for 5 minutes. 2,4,6-Trifluorobenzoyl chloride (1.6 mmol) is added and the reaction mixture is kept at room temperature for 16 hours. HCl (1 M) (10 mL) is added to the mixture to quench the reaction. The mixture is diluted with EtOAc (50 mL), washed with HCl (1 M) (2X10 mL) and brine (50 mL) and dried over anhydrous Na_2SO_4. Purification is accomplished by silica flash chromatography (5 % EtOAc/hexane) to give [5-(4-fluoro-phenyl)-2-(2-methoxy-3-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone as a colorless oil: ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.54 (dd, J_1 = 8.8 Hz, J_2 = 5.3 Hz, 2H), 7.51 (s, 1H), 7.04 (t, J = 8.6 Hz, 2H), 6.95 (t, J = 7.8 Hz, 1H), 6.87 (t, J = 8.8 Hz, 2H), 6.77 (t, J = 7.9 Hz, 2H), 4.03 (s, 3H), 1.27-1.36 (m, 3H), 1.14 (dd, J_1 = J_2 = 6.3 Hz, 18H); LC/MS (ES^+): (M+1) 309.2. R_f = 0.4 (5 % EtOAc/hexanes).

[0065] [5-(4-fluoro-phenyl)-2-(2-methoxy-3-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (0.02 mmol) is treated with tetrabutylammonium fluoride (1 M in THF) (0.04 mmol) at room temperature for 30 minutes.

3-Bromomethyl-benzoic acid methyl ester (0.04 mmol) is then added. After 30 minutes, the reaction is complete as determined by LC/MS. The mixture is diluted with acetonitrile and purified by preparative LC/MS (20-100 % MeCN/H_2O) to give 3-{3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxymethyl}-benzoic acid methyl ester as white solid after evaporation of solvent: ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.14 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.47-7.55 (m, 4H), 7.01-7.07 (m, 3H), 6.94 (t, J = 8.3 Hz, 2H), 6.77 (t, J = 8.5 Hz, 2H), 5.16 (s, 2H), 4.07 (s, 3H), 3.94 (s, 3H). LC/MS (ES^+): (M+1) 610.9.

Example 5

4-{3-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxymethyl}-benzoic acid



[0066] [5-(4-fluoro-phenyl)-2-(2-methoxy-3-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (0.02 mmol) is treated with tetrabutylammonium fluoride (1.0 M in THF) (0.04 mmol) at room temperature for 30 minutes. The reaction is complete by LC/MS analysis. 4-Bromomethyl-benzoic acid methyl ester (0.04 mmol) is added. After 30 minutes, the reaction is complete as determined by LC/MS. After dilution with with MeOH (0.5 mL), LiOH (1 M) (0.5 mL) is added. After stirring for 1 hour, the solvent is removed from the reaction mixture. A mixture of MeOH/DMSO is added to the residue and resultant solution is filtered. The clear solution is

purified by preparative LC/MS (20-100 % MeCN/H_2O) to give 4-{3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxymethyl}-benzoic acid as white solid after removal of solvent: ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.14 (d, J = 8 Hz, 2H), 7.53-7.58 (m, 5H), 7.03-7.05 (m, 3H), 6.94-6.95 (m, 2H), 6.77 (t, J = 8.2 Hz, 2H), 5.2 (s, 2H), 4.08 (s, 3H); LC/MS (ES^+): (M+1) 597.3.

Example 6

2-{2-[5-(4-Chloro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-N-methyl-acetamide



[0067] (2-Formyl-phenoxy)-acetic acid (0.5 mmol) is dissolved in 1 mL of CH_2Cl_2. Oxalyl chloride (0.066 mL) is added along with one drop of DMF. After 1 hour, the solvent is removed from the mixture. The resultant residue is dissolved in 1 mL of CH_2Cl_2 and added to 1 mL of NH_2Me in THF (2 M) at ambient temperature. After 16 hours of stirring, the solvent is removed and the mixture is purified by preparative TLC (10 % MeOH/EtOAc) to yield the product 2-(2-formyl-phenoxy)-N-methyl-acetamide as an off white solid: LC/MS (ES^+): 194.1 $(M+1)^+$.

[0068] The 2-(2-formyl-phenoxy)-N-methyl-acetamide (0.0311 mmol) is added to 4-chloro-thiobenzoic acid hydrazide (0.0342 mmol) in 0.1 mL of CH_2Cl_2. After 10 minutes, DIEA (0.05 mL) and 2,4,6-trifluoro-benzoyl chloride (0.0467 mmol) are added. The mixture is kept at room temperature overnight. After removal of solvent, the residue is purified by preparative HPLC (20-100% MeCN/H_2O gradient) to give the product 2-{2-[5-(4-chloro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-

N-methyl-acetamide as an off white solid: LC/MS (ES^+): 520.1 $(M+1)^+$.

Example 7

N-Cyclopropylmethyl-2-{3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-acetamide



[0069] [5-(4-fluoro-phenyl)-2-(2-methoxy-3-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (3.31 mmol), prepared as described in example 4, is treated with tetrabutylammonium fluoride (1 M in THF) (4.97 mmol) at room temperature for 40 minutes. Methyl bromoacetate (4.97 mmol) is then added. After 12 hours, the reaction is complete as determined by LC/MS. Purification is accomplished by silica flash chromatography (25 % EtOAc/hexane) to give {3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-acetic acid methyl ester: ^1H NMR (400 MHz, $CDCl_3$) δ 7.52 (m, 3H), 7.04 (m, 3H), 6.95 (dd, J_1 = 8.4 Hz, J_2 =1.6 Hz, 1H), 6.82 (dd, J_1 = 8 Hz, J_2 =1.6 Hz), 6.76 (m, 2H), 4.7 (s, 2H), 4.1 (s, 3H); LC/MS (ES^+): 505.1 $(M+1)^+$.

[0070] To a solution of {3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-acetic acid methyl ester (2.47 mmol) in 30 mL of a mixture of THF and MeOH (3:2), is added LiOH (1 M) (25 mL). After stirring for 12 hours the reaction is complete as determined by LC/MS. The reaction is diluted with ethyl acetate and water, washed with brine and dried over $MgSO_4$ and the solvent is removed from the reaction mixture to yield {3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-acetic acid: LC/MS (ES^+): 521.1$(M+1)^+$.

[0071] To a solution of {3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-acetic acid (0.029 mmol) in 1 mL of DMF is added DIEA (0.058 mmol), HATU (0.058 mmol) and cyclopropyl methylamine (0.058 mmol). The reaction mixture is stirred for 12 hours. The mixture is purified by preparative LC/MS (20-100 % MeCN/H_2O) to give N-cyclopropylmethyl-2-{3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-acetamide: ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.55-7.51 (m, 3H), 7.12 - 6.99 (m, 4H), 6.9 (d, J = 7.6 Hz, 2H), 6.77 (t, J = 8.4 Hz, 2H), 4.56 (s, 2H), 4.08 (s, 3H), 3.26–3.2 (m, 2H), 1.02–0.99 (m, 1H), 0.57–0.52 (m, 2H), 0.25 (m, 2H); LC/MS (ES^+): 574.1 $(M+1)^+$.

Example 8

2-{2-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-N-(5-methyl-isoxazol-3-yl)-acetamide



[0072] [5-(4-Fluoro-phenyl)-2-(2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (3.4 mmol), prepared in a similar manner as described for [5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone in example 3, is treated with tetrabutylammonium fluoride (1.0 M in THF) (5.1 mmol) at room temperature for 40 minutes. Methyl bromoacetate (5.1 mmol) is then added. After 12 hours, the reaction is complete as determined by LC/MS. Purification is accomplished by silica flash chromatography (25% EtOAc/hexane) to give {2-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-acetic acid methyl ester: ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.61

(s, 1H), 7.54 (m, 2H), 7.04 (m, 3H), 7.01 (d, J = 8.4 Hz, 1H) 6.95 (bs, 2H), 4.94 (s, 2H), 4.01 (s, 3H). MS: (ES^+) 535.1 (M+1); LC/MS (ES^+): 535.1 $(M+1)^+$.

[0073] To a solution of {2-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-acetic acid methyl ester (2.93 mmol) in 30 mL of a mixture of THF and MeOH (3:2), is added LiOH (1 M) (30 mL). After stirring for 12 hours the reaction is complete as determined by LC/MS. The reaction is diluted with ethyl acetate and water, washed with brine and dried over $MgSO_4$ and the solvent is removed from the reaction mixture to yield {2-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-acetic acid: ^1H NMR (400 MHz, acetone-d_6) δ 7.66 (m, 3H), 7.39 (m, 1H), 7.3 (dd, J_1 = 7.6Hz, J_2 = 1.6Hz, 1H), 7.22 (m, 4H), 7.13 (m, 1H), 7.07 (t, J = 7.6Hz, 1H), 4.94 (s, 2H); LC/MS (ES^+): 491.0 $(M+1)^+$.

[0074] To a solution of {2-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-acetic acid (0.031 mmol) in DMF (1 mL) is added DIEA (0.058 mmol), HATU (0.058 mmol) and 5-methyl-isoxazol-3-ylamine (0.058 mmol). The reaction mixture is stirred for 12 hours. The mixture is purified by preparative LC/MS (20-100% $MeCN/H_2O$) to give 2-{2-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxy}-N-(5-methyl-isoxazol-3-yl)-acetamide: ^1H NMR (400 MHz, $CDCl_3$) δ 7.55–7.51 (m, 3H), 7.35–7.26 (m, 2H), 7.05–6.96 (m, 3H), 6.85 (d, J = 8 Hz, 1H), 6.69 (t, J = 7.6 Hz, 2H), 6.56 (s, 1H), 4.72 (s, 2H), 2.33 (s, 3H); LC/MS (ES^+): 571.1 $(M+1)^+$.

Example 9

3-{2-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxymethyl}-benzamide



[0075] [5-(4-Fluoro-phenyl)-2-(2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (41 μmol), prepared in a similar manner as described for [5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone in example 3, is treated with tetrabutylammonium fluoride (1.0 M in THF) (48 μmol) at room temperature for 40 minutes. The solvent is removed in vacuo and dried over $MgSO_4$ to yield [5-(4-fluoro-phenyl)-2-(2-hydroxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone to be used without further purification.

[0076] To [5-(4-fluoro-phenyl)-2-(2-hydroxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (41 μmol) dissolved in acetonitrile (1 mL) is added K_2CO_3 (61.5 μmol) and 3-bromomethyl-benzamide (94.2 μmol) and the mixture is heated at 90°C. After 12 hours, the reaction is complete as determined by LC/MS. Purification is accomplished by preparative LC/MS (20-100 % $MeCN/H_2O$) to give 3-{2-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxymethyl}-benzamide: ^1H NMR (400 MHz, $CDCl_3$) δ 8.09 (s, 1H), 7.9 (d, J = 7.6Hz, 1H), 7.7 (s, 1H), 7.6-7.5 (m, 4H) 7.35 (d, J = 7.6Hz, 1H), 7.06 (t, J = 8.4Hz, 1H), 6.99 (t, J = 7.6Hz, 2H), 6.88 (d, J = 8Hz), 6.79 (t, J = 8.4Hz, 2H), 6.26 (bs, 1H), 5.33 (d, J = 7.6Hz); LC/MS (ES^+): 566.1 $(M+1)^+$.

Example 10

2-{2-[5(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxymethyl}-furan-3-carboxylic acid



[0077] [5-(4-Fluoro-phenyl)-2-(2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (0.67 mmol), prepared as described for [5-(4-fluoro-phenyl)-2-(3-methoxy-2-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone in example 3, is treated with tetrabutylammonium fluoride (1.0 M in THF) (1.3 mmol) at room temperature. After 15 minutes, methyl 2-(bromomethyl)-3-furoate (0.74 mmol) is added and the mixture is stirred for an additional 12 hours. The solvent is removed *in vacuo* and the residue is purified on silica to yield 2-{2-[5(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxymethyl}-furan-3-carboxylic acid methyl ester as a yellow solid: LC/MS (ES^+): 571.1 $(M+1)^+$.

[0078] To a solution of 2-{2-[5(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxymethyl}-furan-3-carboxylic acid methyl ester (0.49 mmol) in THF/MeOH/H_2O (3:2:1), is added LiOH (3 N) (4.9 mmol). After stirring for 12 hours, the reaction is acidified with HCl (1 N) and extracted with ethyl acetate. The organic layer is dried over $MgSO_4$, filtered, and concentrated. The residue is purified using preparative LC/MS to give 2-{2-[5(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-phenoxymethyl}-furan-3-carboxylic acid as a white solid: ^1H NMR (400 MHz, $CDCl_3$) δ 7.26-7.23 (m, 3H), 7.20 (d, J=1.9, 1H), 7.10-7.05 (m, 1H), 7.03-6.99 (m, 1H), 6.86 (d, J=8.1, 1H), 6.78-6.74 (m, 3H), 6.55 (d, J=1.9, 1H), 6.55-6.50 (m, 2H), 5.38-5.21 (m, 2H); LC/MS (ES^+): 557.1 $(M+1)^+$.

Example 11

[2-(2-Difluoromethoxy-phenyl)-5-(6-methyl-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-

trifluoro-phenyl)-methanone



[0079] N'-(6-Methyl-pyridine-3-carbothioyl)-hydrazinecarboxylic acid *tert*-butyl ester (0.1 mmol) prepared as described in example 3 for N'-(4-fluoro-benzoyl)-hydrazinecarboxylic acid *tert*-butyl ester, is treated with TFA (1 mmol) in dry CH_2Cl_2 (1 mL) at room temperature for 30 minutes. Solvent is removed and the residue is dissolved in dry CH_2Cl_2 (1 mL). DIEA (0.287 mmol) is added to the solution and the mixture is treated with 2-difluoromethoxy-benzaldehyde (0.12 mmol) in the presence of 4 Å molecular sieves. 2,4,6-Trifluorobenzoyl chloride (0.15 mmol) is added after 5 minutes. The mixture is kept at ambient temperature for 16 hours and purified by preparative HPLC (20-100 % MeCN/H_2O) to yield [2-(2-difluoromethoxy-phenyl)-5-(6-methyl-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone: ^{1}H NMR (400 MHz, $CDCl_3$) 8.71 (d, J = 2.1 Hz, 1H), 7.81 (dd, J_1 = 8.2 Hz, J_2 = 2.2 Hz, 1H), 7.53 (s, 1H), 7.36-7.4 (m, 2H), 7.26 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.3 Hz, 1H), 6.78 (t, J = 8.3 Hz, 2H), 6.67 (dd, J_1 = 75.0 Hz, J_2 = 71.7 Hz, 1H), 2.64 (s, 3H); LC/MS (ES^+): (M+1) 480.1.

Example 12

[2-(2-Difluoromethoxy-phenyl)-5-(6-methyl-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2-hydroxy-phenyl)-methanone



[0080] (2-(2-(Difluoromethoxy)phenyl)-5-(6-methylpyridin-3-yl)-1,3,4-thiadiazol-3(2*H*)-yl)(2-acetoxyphenyl)methanone (0.02 mmol) prepared in a similar manner as described in experiment 11 for [2-(2-difluoromethoxy-phenyl)-5-(6-methyl-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone, is dissolved in THF/MeOH (1 mL/0.5 mL) and treated with aqueous LiOH (1 M) (0.5 mL) at room temperature for 30 minutes. Aqueous HCl (3 M) is added to adjust the pH to 5-6. Solvent is removed and the residue is purified by preparative HPLC (20-100 % MeCN/H_2O) to yield [2-(2-difluoromethoxy-phenyl)-5-(6-methyl-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2-hydroxy-phenyl)-methanone: ^{1}H NMR (400 MHz, $CDCl_3$) 9.02 (d, J = 2.0 Hz, 1H), 8.41 (d, J = 8.6 Hz, 1H), 8.23 (dd, J_1 = 8.2 Hz, J_2 = 2.2 Hz, 1H), 7.77 (d, J = 7.5 Hz, 1H), 7.65 (s, 1H), 7.62 (dd, J_1 = 7.8 Hz, J_2 = 1.3 Hz, 1H), 7.45-7.53 (m, 5H), 6.97-7.01 (m, 2H), 2.79 (s, 3H); LC/MS (ES^+): (M+1) 442.1.

Example 13

[2-(2-Difluoromethoxy-phenyl)-5-(6-fluoro-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone



[0081] N'-(6-Fluoro-pyridine-3-carbothioyl)-hydrazinecarboxylic acid *tert*-butyl ester (0.044 mmol) prepared as described in example 3 for N'-(4-fluoro-benzoyl)-hydrazinecarboxylic acid *tert*-butyl ester, is treated with TFA (0.44 mmol) and thioanisole (0.44 mmol) in dry CH_2Cl_2 (1 mL) at room temperature for 30 minutes. The solvent is removed and the residue is dissolved in dry CH_2Cl_2 (1 mL). DIEA (0.22 mmol) is added to the solution and the mixture is treated with 2-difluoromethoxy-benzaldehyde (0.067 mmol) in the presence of 4 Å molecular sieves. 2,4,6-Trifluorobenzoyl chloride (0.089 mmol) is added after 5 minutes. The mixture is kept at room temperature for 16 hours and purified by preparative silica gel TLC (30% EtOAc/hexane) to yield [2-(2-difluoromethoxy-phenyl)-5-(6-fluoro-pyridin-3-yl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone: ^{1}H NMR (400 MHz, $CDCl_3$) 8.39 (s, 1H), 7.93-7.97 (m, 1H), 7.54 (s, 1H), 7.37-7.41 (m, 2H), 7.24-7.27 (m, 1H), 7.19 (d, J = 8.1 Hz, 1H), 6.97 (dd, J_1 = 8.6 Hz, J_2 = 2.7 Hz, 1H), 6.78 (t, J = 8.3 Hz, 2H), 6.67 (dd, J_1 = 75.0 Hz, J_2 = 71.7 Hz, 1H); LC/MS (ES^+): (M+1) 484.1.

Example 14

3-{4-[5-(3,4-Difluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-benzooxazol-2-yl}-benzoic acid



[0082] 2-Amino-3-methyl-phenol (6.09 mmol) is heated with 3-formyl-benzoic acid methyl ester (6.09 mmol) in MeOH (6 mL) at 60 °C for 30 minutes. The solvent is removed from the mixture to obtain a dark red oil which is dissolved in dry CH_2Cl_2 (6 mL) at room temperature and treated with DDQ (6.4 mmol) for 16 hours. The mixture is diluted with

EtOAc and poured onto saturated aqueous $NaHCO_3$. The aqueous phase is further extracted with EtOAc and the combined organic phases are dried over Na_2SO_4. Filtration and removal of the solvent yields a residue which is purified by silica gel chromatography (5-10 % EtOAc/hexane) to yield 3-(4-methyl-benzooxazol-2-yl)-benzoic acid methyl ester as a white solid: ^{1}H NMR (400 MHz, $CDCl_3$) 8.92 (d, J = 1.6 Hz, 1H), 8.47 (dt, J_1 = 7.8 Hz, J_2 = 1.5 Hz, 1H), 8.2 (dt, J_1 = 7.8 Hz, J_2 = 1.4 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.27 (t, J = 7.7 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 3.99 (s, 3H), 2.69 (s, 3H); LC/MS (ES^+): (M+1) 268.1.

[0083] A solution of 3-(4-methyl-benzooxazol-2-yl)-benzoic acid methyl ester (1.2 mmol), N-bromo succinimide (1.5 mmol) and AIBN (0.3 mmol) in CCl_4 are heated in microwave at 100 °C for 30 minutes (1 mL). The mixture is filtered and concentrated to yield the crude 3-(4-bromomethyl-benzooxazol-2-yl)-benzoic acid methyl ester. LC/MS (ES^+): (M^+) 346.1, 348.1, (M-Br) 266.1, 268.1.

[0084] The crude 3-(4-bromomethyl-benzooxazol-2-yl)-benzoic acid methyl ester is treated with HMTA (1.8 mmol) in acetic acid/H_2O (3 mL/1.5 mL) in a microwave oven at 130 °C for 20 minutes. The solvent is removed and the mixture is purified by silica gel chromatography (10-20 % EtOAc/hexane) to yield 3-(4-formyl-benzooxazol-2-yl)-benzoic acid methyl ester as a white solid. Yield: 32 %. ^{1}H NMR (400 MHz, $CDCl_3$) 10.8 (s, 1H), 8.97 (s, 1H), 8.53 (d, J = 7.8 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.94 (dd, J_1 = 7.7 Hz, J_2 = 1 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 4.0 (s, 3H). LC/MS (ES^+): (M+1) 282.1, (M+Na) 304.1.

[0085] N'-(3,4-Difluoro-thiobenzoyl)-hydrazinecarboxylic acid *tert*-butyl ester (0.1 mmol) prepared as described in example 3 for N'-(4-fluoro-benzoyl)-hydrazinecarboxylic acid *tert*-butyl ester, is treated with TFA (1 mmol) in dry CH_2Cl_2 (1 mL) at room temperature for 30 minutes. Solvent is removed and the residue is dissolved in dry CH_2Cl_2 (1 mL). DIEA (0.57 mmol) is added to the solution and the mixture is treated with 3-(4-formyl-benzooxazol-2-yl)-benzoic acid methyl ester (0.064 mmol) in the presence of 4 Å molecular sieves. 2,4,6-Trifluorobenzoyl chloride (0.15 mmol) is added after 5 minutes. The mixture is kept at room temperature for 16 hours and purified by preparative HPLC (20-100 % MeCN/H_2O) to yield 3-{4-[5-(3,4-difluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-benzoo xazol-2-yl}-benzoic acid methyl ester. LC/MS (ES^+): (M+1) 610.0, (M+Na) 632.0.

[0086] 3-{4-[5-(3,4-Difluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-benzooxazol-2-yl}-benzoic acid methyl ester (0.02 mmol) is dissolved in THF/MeOH (1 mL/0.5 mL) and treated with aqueous LiOH (1 M) (0.5 mL) at room temperature for 30 minutes. Aqueous HCl (3 M) is added to adjust the pH to 5-6. The solvent is removed and the residue is purified by preparative HPLC (20-100% $MeCN/H_2O$) to yield 3-{4-[5-(3,4-difluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-benzooxazol-2-yl}-benzoic acid: ^1H NMR (400 MHz, $CDCl_3$) 8.95 (s, 1H), 8.48 (d, J = 7.9 Hz, 1H), 8.27 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.6 (dd, J_1 = 7.7 Hz, J_2 = 1.2 Hz, 1H), 7.46 (m, 1H), 7.29-7.42 (m, 3H), 7.19 (q, J = 8.2 Hz, 1H), 6.76-6.81 (m, 2H); LC/MS (ES^+): (M+1) 596.0, (M+Na) 618.0.

Example 15

5-{3-[5-(4-Fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-furan-2-carboxylic acid



[0087] [5-(4-Fluoro-phenyl)-2-(2-methoxy-3-triisopropylsilanyloxy-phenyl)-[1,3,4]thiadiazol-3-yl]-(2,4,6-trifluoro-phenyl)-methanone (0.03 mmol) prepared as described in example 4, and methyl 5-bromo-2-furate (12 mg, 0.06 mmol) are treated with TBAF (1.0 M in THF) (0.05 mmol) at room temperature under nitrogen. $Pd_2(dba)_3$ (0.003 mmol) and biphenyl-2-yl-di-tert-butyl-phosphane (0.009 mmol) are added along with trifluoromethyl-benzene (0.1 mL) and the mixture is heated in the microwave oven at 150 °C for 30 minutes. After filtration, the solvent is removed and the resultant residue is purified by preparative HPLC (20-100 % $MeCN/H_2O$) to give 5-{3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-furan-2-carboxylic acid methyl

ester: ^{1}H NMR (400 MHz, ppm, $CDCl_3$) 7.51-7.56 (m, 3H), 7.49 (s, 1H), 7.16 -7.18 (m, 1H), 7.04-7.11 (m, 5H), 6.75-6.81 (m, 2H), 4.08 (s, 3H), 3.88 (s, 3H); LC/MS (ES^+): (M-OMe) 555.1, (M+1) 587.1, (M+Na) 609.1.

[0088] The ester is dissolved in THF/MeOH (1 mL/0.5 mL) and treated with aqueous LiOH (1 M) (0.5 mL) at room temperature for 30 minutes. Aqueous HCl (3 M) is added to adjust the pH to 5-6. The solvent is removed and the residue is purified by preparative HPLC (20-100 % MeCN/H_2O) to yield 5-{3-[5-(4-fluoro-phenyl)-3-(2,4,6-trifluoro-benzoyl)-2,3-dihydro-[1,3,4]thiadiazol-2-yl]-2-methoxy-phenoxy}-furan-2-carboxylic acid. ^{1}H NMR (400 MHz, ppm, $CDCl_3$) 7.52-7.56 (m, 3H), 7.49 (s, 1H), 7.19 (dd, J_1 = 7.5 Hz, J_2 = 2.1 Hz, 1H), 7.04-7.15 (m, 5H), 6.78 (t, J = 7.9 Hz, 2H), 4.08 (s, 3H). LC/MS (ES^+): (M-OH) 555.1, (M+1) 573.1, (M+Na) 595.1.

[0089] By repeating the procedures described in the above examples, using appropriate starting materials, the following compounds of Formula I, as identified in Table 1, are obtained.

Table 1

Example	Structure	LCMS (M+1)+	NMR	Synthesis
1		462.8	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.39-7.35 (m, 1H), 7.34-7.29 (m, 4H), 7.25 (dd, J_1 = 7.6 Hz, J_2= 1.2 Hz, 1H), 7.19-7.13 (m, 3H), 7.07-7.03 (m, 1H), 6.99-6.86 (m, 2H), 6.50 (dd, J_1 = 71.6 Hz, J_2= 71.2 Hz, 1H).	Described
2		506.2	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.43 (s, 1H), 7.27 (d, J = 8.6, 2H), 7.15 (m, 2H), 7.14 (d, J = 8.4 Hz, 2H) 6.99 (bs, 1H), 6.84 (t, J = 6.4 Hz, 3H), 6.68 (d, J = 0.4 Hz, 1H), 5.53 (t, J = 6.6 Hz, 2H), 5.29 (bs, 1H), 4.47 (d, J = 1.6 Hz, 2H).	Described
3		520.3	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.63-7.62 (m, 2H), 7.37 (s, 1H), 7.22-7.12 (m, 3H), 7.02 (dd, 2H, J_1 = 0.4 Hz, J_2 = 2 Hz), 6.9 (bs, 1H), 6.85 (t, 2H, J = 0.4Hz), 6.16 (s, 1H), 4.83 (d, 1H, J = 15.2Hz), 4.68 (d, 1H, J = 15.2Hz), 3.94 (s, 3H).	Described
4		616.9	^{1}H NMR (400 MHz, CDCl$_3$) δ 6.14 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.47-7.35 (m, 4H), 7.01-7.07 (m, 3H), 6.94 (t, J = 6.3 Hz, 2H), 6.77 (t, J = 8.5 Hz, 2H), 5.16 (s, 2H), 4.07 (s, 3H), 3.94 (s, 3H).	Described
5		597.3	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.14 (d, J = 8 Hz, 2H), 7.53-7.58 (m, 5H), 7.03-7.05 (m, 3H), 6.94-6.95 (m, 2H), 6.77 (t, J = 0.2 Hz, 2H), 5.2 (s, 2H), 4.06 (s, 3H).	Described
6		520.2		Described
7		574.2	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.56-7.51 (m, 3H), 7.12 - 6.99 (m, 4H), 6.8 (d, J = 7.0 Hz, 2H), 6.77 (t, J = 0.4 Hz, 2H), 4.56 (s, 2H), 4.08 (s, 3H), 3.26--3.2 (m, 2H), 1.02-0.68 (m, 1H), 0.57--0.52 (m, 2H), 0.25 (m, 2H).	Described
8		571.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.55--7.51 (m, 3H), 7.35--7.26 (m, 2H), 7.05--6.96 (m, 3H), 6.85 (d, J = 8 Hz, 1H), 6.69 (d, J = 7.8 Hz, 2H), 6.56 (s, 1H), 4.72 (s, 2H), 2.33 (s, 3H).	Described
9		566.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.09 (s, 1H), 7.9 (d, J = 7 8Hz, 1H), 7.7 (s, 1H), 7.5-7.5 (m, 4H) 7.35 (d, J = 7.0Hz, 1H), 7.06 (t, J = 0.4Hz, 1H), 6.99 (t, J = 7.6Hz, 2H), 6.88 (d, J = 8Hz), 6.79 (t, J = 0.4Hz, 2H), 6.26 (bs, 1H), 5.33 (d, J = 7.6Hz).	Described
10		556.5	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.26-7.23 (m, 3H), 7.20 (d, J =1.9, 1H), 7.10-7.05 (m, 1H), 7.03-6.99 (m, 1H), 6.86 (d, J =8.1, 1H), 6.78-6.74 (m, 3H), 6.55 (d, J =1.9, 1H), 6.36-6.30 (m, 2H), 5.38-5.21 (m, 2H).	Described
11		480.0	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.71 (d, J = 2.1 Hz, 1H), 7.91 (dd, J_1 = 8.2 Hz, J_2 = 2.2 Hz, 1H), 7.53 (s, 1H), 7.36-7.4 (m, 2H), 7.20 (d, J = 0.1 Hz, 2H), 7.18 (d, J = 0 3 Hz, 1H), 0.78 (t, J = 8.3 Hz, 2H), 6.67 (dd, J_1 = 75.0 Hz, J_2 = 71.7 Hz, 1H), 2.64 (s, 3H).	Described
12		442.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 9.02 (d, J = 2.0 Hz, 1H), 8.41 (d, J = 8.6 Hz, 1H), 8.23 (dd, J_1 = 8.2 Hz, J_2 = 2.2 Hz, 1H), 7.77 (d, J = 7.3 Hz, 1H), 7.65 (s, 1H), 7.62 (dd, J_1 = 7.8 Hz, J_2 = 1.3 Hz, 1H), 7.45-7.33 (m, 5H), 6.87-7.01 (m, 2H), 2.79 (s, 3H).	Described
13		484.4	^{1}H NMR (466 MHz, CDCl$_3$) δ 8.39 (s, 1H), 7.83-7.87 (m, 1H), 7.54 (s, 1H), 7.37-7.41 (m, 2H), 7.24-7.27 (m, 1H), 7.19 (d, J = 8.1 Hz, 1H), 6.97 (dd, J_1 = 6.6 Hz, J_2 = 2.7 Hz, 1H), 6.78 (t, J = 8.3 Hz, 2H), 6.67 (dd, J_1 = 75.0 Hz, J_2 = 71.7 Hz, 1H).	Described

14		596.2	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.95 (s, 1H), 8.48 (d, J = 7.9 Hz, 1H), 8.27 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.6 (dd, J_1 = 7.7 Hz, J_2 = 1.2 Hz, 1H), 7.46 (m, 1H), 7.26-7.42 (m, 3H), 7.19 (s, J = 8.2 Hz, 1H), 6.76-6.81 (m, 2H).	Described
15		573.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.52-7.56 (m, 3H), 7.49 (s, 1H), 7.19 (dd, J_1 = 7.5 Hz, J_2 = 2.1 Hz, 1H), 7.04-7.15 (m, 5H), 6.78 (t, J = 7.9 Hz, 2H), 4.08 (s, 3H).	Described
16		557.1		Synthesized as described in example 15
17		543.1		Synthesized as described in example 15
18		503.0		Synthesized as described in example 1
19		529.1		Synthesized as described in example 1
20		513.0		Synthesized as described in example 1
21		508.0	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.21 (s, 1H), 8.82 (s, 1H), 8.44 (s, 1H), 7.68 (dd, J_1 = 8.6 Hz, J_2 = 5.2 Hz, 2H), 7.54 (s, 1H), 7.34-7.39 (m, 3H), 7.18-7.26 (m, 2H), 7.13 (t, J = 8.5 Hz, 2H), 6.69 (dd, J_1 = 79 Hz, J_2 = 7.1 Hz, 1H).	Synthesized as described in example 4
22		535.3	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.5-7.55 (m, 3H), 7.04 (s, J = 8.8 Hz, 4H), 8.95 (dd, J_1 = 7.9 Hz, J_2 = 1.2 Hz, 1H), 8.61 (dd, J_1 = 8.1 Hz, J_2 = 1.3 Hz, 1H), 8.77 (t, J = 8.3 Hz, 1H), 4.7 (s, 2H), 4.1 (s ,3H), 3.82 (s, 3H).	Synthesized as described in example 3
23		509.2		Synthesized as described in example 1
24		502.2		Synthesized as described in example 1
25		587.3	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.21 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.51-7.55 (m, 4H), 7.05 (m, 3H), 6.95 (t, J = 8.6 Hz, 2H), 6.77 (t, J = 8.3 Hz, 2H), 5.18 (s, 2H), 4.08 (s, 3H).	Synthesized as described in example 5
26		479.0		Synthesized as described in example 1

27		479.3		Synthesized as described in example 1
28		520.3	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.54 (m, 2H), 7.5 (s, 1H), 7.07-7.13 (m, 4H), 6.92 (d, J = 8.2 Hz, 1H), 6.82 (s, 1H), 6.77 (t, J = 8.3 Hz, 1H), 5.79 (s, 1H), 4.58 (s, 2H), 4.06 (s, 3H).	Synthesized as described in example 4
29		626.3		Synthesized as described in example 1
30		811.2		Synthesized as described in example 5
31		598.2		Synthesized as described in example 3
32		447.0	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.76 (d, J = 7.7 Hz, 1H), 7.73 (d, J = 9.8 Hz, 1H), 7.66 (dd, J_1 = 8.7 Hz, J_2 = 5.3 Hz, 2H), 7.56 (s, 1H), 7.44 (s, J = 8.0 Hz, 1H), 7.33-7.37 (m, 2H), 7.17-7.26 (m, 3H), 7.12 (t, J = 8.5 Hz, 2H), 6.7 (dd, J_1 = 76 Hz, J_2 = 71 Hz, 1H).	Synthesized as described in example 1
33		479.3		Synthesized as described in example 1
34		461.2		Synthesized as described in example 1
35		518.2	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.39 (s, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.02 (t, 1H), 6.82 (t, J = 8.0 Hz, 2H), 6.62 (t, J = 8.0 Hz, 2H), 4.55 (d, J = 6.8 Hz, 2H), 3.78 (s, 3H).	Synthesized as described in example 1
36		483.0	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.54 (dd, J_1 = 8.7 Hz, J_2 = 5.2 Hz, 2H), 7.5 (s, 1H), 7.4 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.06 (t, J = 8.5 Hz, 2H), 6.77 (t, J = 8.4 Hz, 2H), 6.68 (dd, J_1 = 75 Hz, J_2 = 72 Hz, 1H).	Synthesized as described in example 1
37		558.2		Synthesized as described in example 4
38		481.0		Synthesized as described in example 1
39		495.0		Synthesized as described in example 1

40		489.0		Synthesized as described in example 1
41		443.0	^{1}H NMR (400 MHz, CDCl$_3$) 7.4-7.44 (m, 2H), 7.23-7.32 (m, 3H), 7.12-7.16 (m, 2H), 7.08 (t, J = 7.9 Hz, 1H), 6.93 (t, J = 8.5 Hz, 2H), 6.6 (dd, J_1 = 7.1 Hz, J_2 = 76 Hz, 1H), 2.24 (s, 3H).	Synthesized as described in example 1
42		561.3		Synthesized as described in example 3
43		562.1		Synthesized as described in example 3
44		589.9		Synthesized as described in example 3
45		490.2		Synthesized as described in example 1
46		479.2		Synthesized as described in example 1
47		514.9		Synthesized as described in example 1
48		518.0	^{1}H NMR (400 MHz, CDCl3) δ 7.46-7.35 (m, 3H), 7.22 (d, 2H, J = 8.6 Hz), 7.05 (t, 1H, J = 8Hz), 6.85-6.80 (m, 2H), 6.63 (m, 2H), 4.67 (d, 2H, J = 7.2 Hz), 3.79 (s, 3H).	Synthesized as described in example 1
49		493.0		Described as described in example 10
50		517.0		Synthesized as described in example 1
51		463.0		Synthesized as described in example 1
52		639.3		Synthesized as described in example 4

53		451.1		Synthesized as described in example 1
54		476.6		Synthesized as described in example 1
55		532.3		Synthesized as described in example 1
56		492.6		Synthesized as described in example 1
57		479.0		Synthesized as described in example 1
58		459.0		Synthesized as described in example 1
59		509.3	^{1}H NMR (400MHz, CDCl$_3$) δ 7.88-7.85 (m, 2H), 7.71 (t, 1H, J = 7.6 Hz), 7.67-7.62 (m, 2H), 7.55 (t, 1H), 7.11 (t, 2H, J = 11.8 Hz), 7.03(t, 1H, J = 8Hz), 6.90 (dd, 1H, J_1 = 8Hz, J_2 = 1.6Hz), 6.82 (dd, 1H, J_1 = 7.6 Hz, J_2 = 12 Hz), 4.03 (s, 3H), 3.86 (s, 3H)	Synthesized as described in example 1
60		443.0	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.79 (d, J = 8.2 Hz, 1H), 7.76 (s, 1H), 7.66 (dd, J_1 = 8.7 Hz, J_2 = 5.3 Hz, 2H), 7.56 (s, 1H), 7.32-7.37 (m, 4H), 7.19 (d, J = 7.6 Hz, 2H), 7.1 (t, J = 8.5 Hz, 2H), 6.71 (dd, J_1 = 7.1 Hz, J_2 = 76 Hz, 1H), 2.42 (s, 3H).	Synthesized as described in example 1
61		490.2	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.88 (s, 1H), 7.49 (m, 2H), 7.33 (dd, J_1 = 7.6 Hz, J_2 = 1.2 Hz, 1H), 7.25 (dd, J_1 = 8.4 Hz, J_2 = 1.2 Hz, 1H), 7.13 (bs, 1H), 6.99 (m, 3H), 6.81 (d, J = 8 Hz, 1H), 6.68 (t, J = 8.4 Hz, 2H), 5.76 (bs, 1H), 4.81 (d, J = 1.6 Hz, 2H).	Synthesized as described in example 2
62		459.0	^{1}H NMR (400MHz, CDCl$_3$) δ 7.91 (d, 2H, J = 8 Hz), 7.61-7.57 (m, 3H), 7.39-7.30 (m, 4H), 7.29-7.26 (m, 2H), 7.21-7.16 (m, 2H), 6.70(dd,1H, J_1 = 76 Hz, J_2 = 71.2 Hz).	Synthesized as described in example 1
63		472.9		Synthesized as described in example 1
64		544.8		Synthesized as described in example 1
65		611.3		Synthesized as described in example 5

66		625.1		Synthesized as described in example 4
67		517.3		Synthesized in a similar way as described in example 4
68		507.3	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.53 (dd, J_1 = 8.7 Hz, J_2 = 5.3 Hz, 2H), 7.5 (s, 1H), 7.03-7.08 (m, 3H), 6.84 (d, J = 8.4 Hz, 2H), 6.77 (t, J = 8.5 Hz, 2H), 4.15 (t, J = 4.3 Hz, 2H), 4.05 (s, 3H), 3.58-4.02 (m, 2H).	Synthesized in a similar way as described in example 4
69		810.3	^{1}H NMR (400MHz, CDCl$_3$) δ 8.05 (d, 1H, J = 8 Hz), 7.95 (d, 1H, J = 8 Hz), 7.65 (s, 1H), 7.53-7.42 (m, 4H), 7.13 (t, 1H, J = 8 Hz), 7.03-6.94 (m, 4H), 6.77 (bs, 2H), 5.7 (s, 2H), 3.90 (s, 3H).	Synthesized as described in example 1
70		558.3		Synthesized as described in example 3
71		504.1	^{1}H NMR (400MHz, CDCl$_3$) δ 7.63 (s, 1H), 7.5-7.55 (m, 2H), 7.41-7.38 (m, 1H), 7.35-7.31 (m, 1H), 7.25-7.21 (bs, 1H), 7.11-7.04 (m, 3H), 6.87 (d, J = 8.4 Hz, 1H), 6.78 (t, J = 8.4 Hz, 1H), 4.89 (d, J = 7.2 Hz, 2H), 2.81 (d, J = 4.8Hz, 3H).	Synthesized as described in example 8
72		518.3		Synthesized as described in example 8
73		574.4		Synthesized as described in example 8
74		590.4		Synthesized as described in example 8
75		580.3		Synthesized as described in example 8
76		584.4		Synthesized as described in example 8
77		567.3		Synthesized as described in example 8
78		559.1		Synthesized as described in example 5

79		571.3		Synthesized as described in example 5
80		587.2		Synthesized as described in example 4
81		598.1		Synthesized as described in example 5
82		627.1		Synthesized as described in example 5
83		627.1		Synthesized as described in example 5
84		566.2		Synthesized as described in example 7
85		591.2	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.35 (m, 4H), 6.89-6.99 (m, 6H), 4.38 (s, 2H), 3.8 (s, 3H), 3.44 (m, 1H), 3.32 (m, 1H), 2.29 (s, 1H)	Synthesized as described in example 7
86		472.0		Described as described in example 10
87		567.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.53 (dd, J_1 = 8.7 Hz, J_2 = 5.3 Hz, 2H), 7.5 (b, 1H), 7.18 (d, J = 3.4 Hz, 1H), 7.02-7.07 (m, 3H), 6.94-6.97 (m, 2H), 6.77 (t, J = 8.4 Hz, 2H), 6.54 (d, J = 3.4 Hz, 1H), 5.12 (s, 2H), 4.04 (s, 3H), 3.9 (s, 3H)	Described as described in example 8
88		568.1		Synthesized as described in example 8
89		568.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.53 (dd, J_1 = 8.9 Hz, J_2 = 5.2 Hz, 2H), 7.5 (b, 1H), 7.3 (d, J = 3.5 Hz, 1H), 7.03-7.07 (m, 3H), 6.95 (d, J = 6.3 Hz, 2H), 6.77 (t, J = 8.3 Hz, 2H), 6.55 (d, J = 3.5 Hz, 1H), 5.15 (s, 2H), 4.05 (s, 3H), 2.9 (bs, 1H).	Synthesized as described in example 5
90		612.2		Synthesized as described in example 4
91		601.0	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.53 (dd, J_1 = 8.7 Hz, J_2 = 5.3 Hz, 2H), 7.5 (b, 1H), 7.18 (d, J = 3.4 Hz, 1H), 7.02-7.07 (m, 3H), 6.94-6.97 (m, 2H), 6.77 (t, J = 8.4 Hz, 2H), 6.54 (d, J = 3.4 Hz, 1H), 5.12 (s, 2H), 4.04 (s, 3H), 3.9 (s, 3H).	Synthesized as described in example 4

92		648.2		Synthesized as described in example 7
93		573.1		Synthesized as described in example 8
94		518.0	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.39 (s, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.02 (t, 1H), 6.82 (t, J = 8.0 Hz, 2H), 6.82 (t, J = 8.0 Hz, 2H), 4.86 (d, J = 6.8 Hz, 2H), 3.78 (s, 3H).	Synthesized as described in example 1 followed by chiral HPLC
95		615.2		Synthesized as described in example 7
96		696.2		Synthesized as described in example 7
97		544.2		Synthesized as described in example 8
98		647.2		Synthesized as described in example 7
99		605.2	^{1}H NMR (400MHz, $CDCl_3$) δ 7.74 - 7.7 (m, 3H), 7.3 - 7.19 (m, 4H), 7.11 (d, J = 8.4 Hz, 1H), 6.97 (t, J_1 = 8.4 Hz, J_2 = 2 Hz), 6.33 (bs, 1H), 4.78 (s, 2H), 4.27 (s, 3H), 3.74–3.54 (m, 4H), 2.3 (s, 1H), 2.15 (s, 3H).	Synthesized as described in example 7
100		490.0	^{1}H NMR (400MHz, $CDCl_3$) δ 7.63-7.62 (m, 2H), 7.57 (s, 1H), 7.22-7.12 (m, 3H), 7.02 (dd, 2H, J_1 = 8.4 Hz, J_2 = 2 Hz), 6.8 (bs, 1H), 6.65 (t, 2H, J = 8.4 Hz), 6.10 (s, 1H), 4.83 (d, 1H, J = 15.2 Hz), 4.66 (d, 1H, J = 15.2 Hz), 3.94 (s, 3H).	Synthesized as described in example 2 followed by chiral HPLC
101		559.1		Synthesized as described in example 5
102		654.2		Synthesized as described in example 7
103		576.2		Synthesized as described in example 8
104		653.2		Synthesized as described in example 7

105		568.1		Synthesized as described in example 5
106		585.2		Synthesized as described in example 8
107		526.0		Synthesized as described in example 9
108		568.1		Synthesized as described in example 6
109		597.2		Synthesized as described in example 10
110		604.2		Synthesized as described in example 7
111		598.2	^{1}H NMR (400MHz, CDCl$_3$) δ 9.33 (bs, 1H), 9.02 (s, 1H), 8.77 (d, J = 6 Hz, 1H), 8.31 (d, J = 9 Hz, 1H), 7.63-7.60 (m, 3H), 7.22 - 7.12 (m, 4H), 7.04 (d, J = 8 Hz, 1H), 6.86 (t, J = 8 Hz, 2H), 4.6 (s, 2H), 4.23 (s, 3H).	Synthesized as described in example 7
112		497.1		Synthesized as described in example 4
113		575.1		Synthesized as described in example 6
114		506.0	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.43 (s, 1H), 7.27 (d, J = 8.8, 2H), 7.15 (m, 2H), 7.14 (d, J = 8.4 Hz, 2H) 6.99 (bs, 1H), 6.84 (t, J = 6.4 Hz, 3H), 6.66 (d, J = 8.4 Hz, 1H), 6.53 (t, J = 8.0 Hz, 2H), 5.29 (bs, 1H), 4.47 (d, J = 1.6 Hz, 2H).	Synthesized as described in example 2 followed by chiral HPLC
115		670.2 [M+23]		Synthesized as described in example 7
116		606.2		Synthesized as described in example 7
117		712.2		Synthesized as described in example 7

118		582.0		Synthesized as described in example 9
119		580.9		Synthesized as described in example 9
120		614.1		Synthesized in a similar way as described in example 7
121		648.2		Synthesized as described in example 8
122		524.9		Synthesized as described in example 9
123		564.2		Synthesized as described in example 8
124		659.1		Synthesized as described in example 4
125		617.1		Synthesized as described in example 7
126		678.2		Synthesized as described in example 7
127		640.2 [M+23]		Synthesized as described in example 8
128		601.2		Synthesized as described in example 9
129		646.2		Synthesized as described in example 7
130		603.1		Synthesized as described in example 7
131		641.1		Synthesized as described in example 4

132		595.2	^{1}H NMR (400MHz, CDCl$_3$) δ 7.41-7.36 (m, 3H), 7.32(d, J = 6 Hz, 2H), 7.26(d, J = 7.6 Hz, 2H), 7.16 (m, 1H), 6.92-6.85 (m, 4H), 6.72 - 6.58 (m, 3H), 5.85 (s, 2H), 3.59 (s, 3H), 3.53 (s, 2H).	Synthesized in a similar way as described in example 4
133		552.1		Synthesized as described in example 9
134		587.1		Synthesized as described in example 8
135		602.1		Synthesized as described in example 8
136		675.2		Synthesized as described in example 7
137		567.1		Synthesized as described in example 10
138		617.1		Synthesized as described in example 7
139		660.2		Synthesized as described in example 7
140		616.2		Synthesized as described in example 8
141		608.2		Synthesized as described in example 7
142		645.2		Synthesized as described in example 8
143		624.2		Synthesized as described in example 8
144		590.2		Synthesized as described in example 4
145		632.1		Synthesized as described in example 7

146		597.1		Synthesized as described in example 5 followed by chiral HPLC
147		609.2	^{1}H NMR (400MHz, CDCl$_3$) δ 7.53-7.50 (m, 3H), 7.47-7.35 (m, 3H), 7.32-7.26 (m, 3H), 7.05-6.97 (m, 4H), 6.77 (m, 2H), 5.18 (s, 2H), 4.18 (q, J = 7.2 Hz, 2H), 3.66 (s, 2H), 1.26 (t, J = 3.2 Hz, 3H).	Synthesized in a similar way as described in example 10
148		445.0		Synthesized as described in example 1
149		495.1		Synthesized as described in example 1
150		582.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 9.23 (s, 1H), 8.44 (dd, J_1 = 8.2 Hz, J_2 = 2.0 Hz, 1H), 7.8 (d, J = 8.2 Hz, 1H), 7.62 (s, 1H), 7.49-7.53 (m, 2H), 7.29-7.38 (m, 2H), 7.02-7.06 (m, 3H), 6.94 (d, J = 8.2 Hz, 1H), 6.79 (m, 2H), 5.48 (s, 2H), 3.46 (s, 3H).	Synthesized as described in example 10
151		572.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.25 (s, 1H), 7.48-7.52 (m, 3H), 7.26-7.35 (m, 2H), 7.01-7.00 (m, 4H), 6.78 (m, 2H), 5.32 (d, J = 2.3 Hz, 2H), 3.94 (s, 3H).	Synthesized as described in example 10
152		583.1		Synthesized as described in example 10
153		571.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.48-7.52 (m, 3H), 7.42 (d, J = 2.0 Hz, 1H), 7.32 (dd, J_1 = 7.8 Hz, J_2 = 1.8 Hz, 1H), 7.24 (m, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.88-7.05 (m, 3H), 6.72-6.81 (m, 3H), 5.49 (d, J = 8.1 Hz, 2H), 3.88 (s, 3H).	Synthesized as described in example 10
154		612.2	^{1}H NMR (400 MHz, CDCl$_3$) δ 9.24 (d, J = 1.8 Hz, 1H), 8.46 (dd, J_1 = 8.2 Hz, J_2 = 2.0 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.52-7.56 (m, 3H), 7.05 (dt, J_1 = 8.5 Hz, J_2 = 2.8 Hz, 3H), 6.96 (d, J = 7.9 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 6.77 (d, J = 8.4 Hz, 2H), 5.37 (s, 2H), 4.11 (s, 3H), 3.88 (s, 3H).	Synthesized as described in example 4
155		602.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.28 (s, 1H), 7.53 (m, 3H), 7.49 (s, 1H), 7.02-7.07 (m, 4H), 6.97 (dd, J1 = 8.0 Hz, J2 = 3.2 Hz, 1H), 6.77 (t, J = 8.2 Hz, 2H), 5.25 (d, J = 1.8 Hz, 2H), 4.05 (s, 3H), 3.94 (s, 3H).	Synthesized as described in example 4
156		601.2		Synthesized as described in example 4
157		588.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.35 (s, 1H), 7.53 (d, J = 8.7 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.49 (s, 1H), 7.01-7.07 (m, 4H), 6.98 (d, J = 7.2 Hz, 1H), 6.77 (t, J = 8.2 Hz, 2H), 5.26 (s, 2H), 4.05 (s, 3H).	Synthesized as described in example 5
158		588.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.54 (dd, J_1 = 8.8 Hz, J_2 = 5.2 Hz, 2H), 7.5 (s, 1H), 7.03-7.09 (m, 3H), 7.0 (dd, J_1 = 8.7 Hz, J_2 = 1.2 Hz, 1H), 6.95 (dd, J_1 = 8.0 Hz, J_2 = 1.2 Hz, 1H), 6.84 (s, 1H), 6.77 (t, J = 8.2 Hz, 2H), 5.27 (s, 2H), 4.05 (s, 3H).	Synthesized as described in example 5

159		587.1	^{1}H NMR (400 MHz, ppm, $CDCl_3$) 7.51-7.55 (m, 2H), 7.5 (s, 1H), 7.45 (d, J = 1.9 Hz, 1H), 6.99-7.07 (m, 1H), 6.84 (dd, J_1 = 7.1 Hz, J_2 = 2.0 Hz, 1H), 6.77 (t, J = 8 Hz, 2H), 5.48 (d, J = 12.7 Hz, 2H), 5.38 (d, J = 12.5 Hz, 1H), 4 (M (s, 3H)	Synthesized as described in example 5
160		592.2		Synthesized in esimilar way as described in example 8
161		508.1		Synthesized in a similar way as described in example 8
162		592.2		Synthesized in a similar way as described in example 8
163		585.2		Synthesized in a similar way as described in example 8
164		508.1		Described in a similar way as described in example 9
165		566.1		Synthesized as described in example 9
166		596.1		Described in a similar way as described in example 9
167		596.2		Described in a similar way as described in example 9
168		632.1		Described in a similar way as described in example 8
169		581.1		Synthesized as described in example 8
170		581.1		Synthesized as described in example 9
171		642.1		Synthesized as described in example 8

172		614.1		Synthesized as described in example 6
173		658.1		Synthesized as described in example 8
174		572.1		Synthesized as described in example 8
175		576.2		Synthesized as described in example 8
176		536.1	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.79-7.77 (m, 2H), 7.73-7.69 (m, 2H), 7.55 (dd, J_1 = 8.1 Hz, J_2 = 1.5 Hz, 1H), 7.50-7.45 (m, 1H), 7.24-7.18 (m, 3H), 7.02 (d, J = 8.1 Hz, 1H), 6.92-6.87 (m, 2H), 4.89 (d, J = 6.8 Hz, 2H), 4.66-4.63 (m, 1H), 4.54-4.51 (m, 1H), 3.84-3.62 (m, 2H).	Synthesized as described in example 8
177		550.2		Synthesized as described in example 8
178		564.1		Synthesized as described in example 8
179		546.2		Synthesized as described in example 8
180		560.2		Synthesized as described in example 8
181		484.0	^{1}H NMR (400 MHz, CDCl$_3$) δ 8.75 (d, J = 1.8 Hz, 1H), 8.17 (dd, J_1 = 5.3 Hz, J_2 = 1.9 Hz, 1H), 7.52-7.81 (m, 3H), 7.31-7.44 (m, 4H), 7.18-7.24 (m, 3H), 5.09 (dd, J_1 = 75.2 Hz, J_2 = 71.6 Hz, 1H), 2.75 (s, 3H), 2.10 (s, 3H).	Synthesized as described in example 11
182		530.1		Synthesized as described in example 8
183		568.2		Synthesized as described in example 8
184		568.2	^{1}H NMR (400 MHz, CDCl$_3$) δ 7.55 (s, 1H), 7.46-7.41 (m, 2H), 7.24-7.18 (m, 2H), 6.95-6.92 (m, 4H), 6.79 (d, J = 8.2 Hz, 1H), 6.68-6.63 (m, 2H), 5.76 (d, J = 2.3 Hz, 1H), 4.90-4.87 (m, 2H), 2.30 (s, 3H), 2.16 (s, 3H)	Synthesized as described in example 8

185		557.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.31 (s, 1H), 8.09 (d, J = 1.6 Hz, 1H), 7.43-7.39 (m, 3H), 7.24 (dt, J_1 = 5.9 Hz, J_2 = 1.5 Hz, 1H), 7.19-7.15 (m, 1H), 6.93-6.84 (m, 3H), 6.78 (d, J = 1.6 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 6.61-6.52 (m, 2H), 4.62 (s, 2H)...	Synthesized as described in example 6
186		594.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 8.69 (d, J = 1.4 Hz, 1H), 8.1 (bs, J_1 = 8.1 Hz, J_2 = 1.4 Hz, 1H), 8.07 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.56 (s, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 6.83 (d, J = 6.9 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 6.54 (t, J = 6.4 Hz, 2H), 5.22 (bs, J_1 = 30.2 Hz, J_2 = 12.2 Hz, 2H), 4.05 (s, 3H), 3.76 (s, 3H).	Synthesized as described in example 5
187		568.2		Synthesized as described in example 4
188		459.2		Synthesized as described in example 4
189		537.1		Synthesized as described in example 4
190		532.1		Synthesized as described in example 4
191		471.1		Synthesized as described in example 4
192		468.2		Synthesized as described in example 4
193		487.2		Synthesized as described in example 4
194		530.2		Synthesized as described in example 4
195		565.2		Synthesized as described in example 4
196		560.1		Synthesized as described in example 4
197		499.1		Synthesized as described in example 4

198		472.2		Synthesized as described in example 4
199		550.2		Synthesized as described in example 4
200		659.6		Synthesized as described in example 7
201		631.2		Synthesized as described in example 7
202		609.2		Synthesized as described in example 5
203		605.2		Synthesized as described in example 7
204		631.2		Synthesized as described in example 7
205		631.2		Synthesized as described in example 7
206		590.2	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.55-7.51 (m, 2H), 7.50 (s, 1H), 7.12-7.04 (m, 3H), 7.02 (dd, J_1 = 8.6 Hz, J_2 = 1.1 Hz, 1H), 6.90 (dd, J_1 = 8.6 Hz, J_2 = 1.2 Hz, 1H), 6.83 (bs, 1H), 6.79-6.75 (m, 2H), 4.58 (s, 2H), 4.05 (s, 3H), 3.40-3.35 (m, 2H), 1.65-1.58 (m, 1H), 1.48-1.42 (m, 2H), 0.930 (d, J = 6.6 Hz, 6H).	Synthesized as described in example 7
207		625.2		Synthesized as described in example 7
208		653.09		Synthesized as described in example 7
209		633.2		Synthesized as described in example 7
210		444.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 8.37 (s, 1H), 7.95 (dt, J_1 = 8.5 Hz, J_2 = 2.3 Hz, 1H), 7.59 (s, 1H), 7.35-7.43 (m, 4H), 7.18-7.26 (m, 2H), 7.19 (d, J = 8.2 Hz, 1H), 6.94 (dd, J_1 = 8.6 Hz, J_2 = 2.6 Hz, 1H), 6.7 (dd, J_1 = 76.1 Hz, J_2 = 71 Hz, 1H).	Synthesized as described in example 13

211		648.2		Synthesized as described in example 7
212		611.2		Synthesized as described in example 7
213		660.3		Synthesized as described in example 7
214		591.2		Synthesized as described in example 7
215		632.2		Synthesized as described in example 7
216		659.3		Synthesized as described in example 7
217		679.2		Synthesized as described in example 5
218		625.2		Synthesized as described in example 7
219		625.2		Synthesized as described in example 7
220		628.2		Synthesized as described in example 7
221		557.2		Synthesized as described in example 5
222		629.2		Synthesized as described in example 5
223		620.2		Synthesized as described in example 7
224		549.2		Synthesized as described in example 5

225		689.1		Synthesized as described in example 7
226		622.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.26 (s, 1H), 8.83 (s, 1H), 8.51 (s, 1H), 8.15 (d, J = 8.2 Hz, 2H), 7.88 (dd, J_1 = 8.7 Hz, J_2 = 5.2 Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 7.56 (s, 1H), 7.12 (t, J = 8.5 Hz, 2H), 7.02 (t, J = 8.0 Hz, 1H), 6.93 (dd, J_1 = 8.2 Hz, J_2 = 1.1 Hz, 1H), 6.86 (dd, J_1 = 7.7 Hz, J_2 = 1.0 Hz, 1H), 5.2 (s, 2H), 4.06 (s, 3H).	Synthesized as described in example 5
227		525.2		Synthesized as described in example 5
228		576.2	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.64-7.61 (m, 2H), 7.58 (s, 1H), 7.21-7.13 (m, 3H), 7.09 (dd, J_1 = 8.5 Hz, J_2 = 1.1 Hz, 1H), 7.05 (bs, 1H), 7.01 (dd, J_1 = 8.7 Hz, J_2 = 1.3 Hz, 1H), 6.87 (m, 2H), 4.69 (s, 2H), 4.15 (s, 3H), 3.29 (t, J = 6.8 Hz, 2H), 1.56-1.88 (m, 1H), 1.03 (d, J = 6.6 Hz, 6H).	Synthesized as described in example 7
229		620.2		Synthesized as described in example 7
230		579.2		Synthesized as described in example 6
231		668.2		Synthesized as described in example 7
232		645.2		Synthesized as described in example 7
233		551.1		Synthesized as described in example 5
234		630.2		Synthesized as described in example 7
235		619.2		Synthesized as described in example 6
236		610.2		Synthesized as described in example 14
237		567.1		Synthesized as described in example 5

238		587.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.54 (d, J = 8.8 Hz, 2H), 7.53 (t, J = 8.7 Hz, 1H), 7.5 (s, 1H), 7.31 (d, J = 3.5 Hz, 1H), 7.03-7.07 (m, 3H), 6.97 (d, J = 2.2 Hz, 1H), 6.95 (s, 1H), 6.77 (t, J = 8.3 Hz, 2H), 6.59 (d, J = 3.5 Hz, 1H), 5.15 (d, 2H), 4.05 (s, 3H).	Synthesized as described in example 5
239		592.2		Synthesized as described in example 7
240		469.1		Synthesized as described in example 4
241		617.2		Synthesized as described in example 5
242		598.2	^{1}H NMR (400 MHz, $CDCl_3$) δ 8.2 (d, J = 7.7 Hz, 1H), 8.03 (t, J = 7.8 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.52-7.58 (m, 3H), 7.03-7.08 (m, 3H), 6.97 (d, J = 7.9 Hz, 1H), 6.92 (d, J =7.1 Hz, 1H), 6.77 (t, J = 8.4 Hz, 2H), 5.32 (s, 2H), 4.11 (s, 3H).	Synthesized as described in example 5
243		625.2	^{1}H NMR (400 MHz, $CDCl_3$) δ 8.91 (bs, 1H), 7.82 (s, 1H), 7.46-7.42 (m, 3H), 7.00-6.88 (m, 5H), 6.59-6.55 (m, 3H), 4.58 (s, 2H), 4.05 (s, 3H), 2.34 (s, 3H), 2.25 (s, 3H).	Synthesized as described in example 7
244		539.1	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.70 (m, 2H), 7.52 Hz, J_2 = 8.8 Hz, 2H), 7.28 (m, 2H), 7.11 (m, 2H), 6.9 (m, 2H), 6.74 (dd, 1H), 6.56 (d, J = 3.6 Hz, 1H), 5.11 (s, 2H), 3.98 (s, 3H), 3.24 (m, 1H), 2.08 (m, 1H), 1.90-1.83 (m, 3H), 1.72 (m, 1H), 1.59-1.3 (m, 5H).	Synthesized as described in example 5
245		611.2		Synthesized as described in example 7
246		569.1		Synthesized as described in example 5

Assay1 - Transcriptional Assay

[0090] Transfection assays are used to assess the ability of compounds of the invention to modulate the transcriptional activity of the LXRs. Briefly, expression vectors for chimeric proteins containing the DNA binding domain of yeast GAL4 fused to the ligand-binding domain (LBD) of either LXRα or LXRβ are introduced via transient transfection into mammalian cells, together with a reporter plasmid where the luciferase gene is under the control of a GAL4 binding site. Upon exposure to an LXR modulator, LXR transcriptional activity varies, and this can be monitored by changes in luciferase levels. If transfected cells are exposed to an LXR agonist, LXR-dependent transcriptional activity increases and luciferase levels rise.

[0091] 293T human embryonic kidney cells ($8x10^6$) are seeded in a $175cm^2$ flask 2 days prior to the start of the experiment in 10% FBS, 1% Penicillin/Streptomycin/Fungizome, DMEM Media. The transfection mixture for chimeric proteins is prepared using GAL4-LXR LBD expression plasmid (4μg), UAS-luciferase reporter plasmid (5μg), Fugene (3:1 ratio; 27μL) and serum-free media (210μL). The transfection mixture is incubated for 20 minutes at room temperature. The cells are harvested by washing with PBS (30ml) and then dissociating using trypsin (0.05%; 3ml). The trypsin is inactivated by the addition of assay media (DMEM, lipoprotein-deficient fetal bovine serum (5%), statin (e.g. lovastatin 7.5μM), and mevalonic acid (100μM)) (10ml). The cells are counted using a 1:10 dilution and the concentration of cells adjusted to 160,000cells/ml. The cells are further incubated for 30 minutes at room temperature with periodic mixing by inversion. Transfection mixtures are added to the cells, and cells (50μl/well) are then plated into 384 white, solid-bottom, TC-treated plates. The cells are further incubated at 37°C, 5.0% CO_2 for 24 hours. A 12-point series of dilutions (half-log serial dilutions) are prepared for each test compound in DMSO with a starting concentration of compound of 1μM. Test compound (500nl) is added to each well of cells in the assay plate and the cells are incubated at 37°C, 5.0% CO_2 for 24 hours. The cell lysis/luciferase assay buffer, Bright-Glo™ (25%; 25μl; Promega), is added to each well. After a further incubation for 5 minutes at room temperature, the luciferase activity is measured.

[0092] Raw luminescence values are normalized by dividing them by the value of the DMSO control present on each plate. Normalized data is visualized using XLfit3 and dose-response curves are fitted using a 4-parameter logistic model or sigmoidal single-site dose-response equation (equation 205 in XLfit3.05). EC50 is defined as the concentration at which the compound elicits a response that is half way between the maximum and minimum values. Relative efficacy (or percent efficacy) is calculated by comparison of the response elicited by the compound with the maximum value obtained for a reference LXR modulator.

Assay2 - FRET Co-activator Recruitment Assay

[0093] A FRET assay is used to assess the ability of a compound of the invention to bind directly to the LXR ligand-binding domain (LBD) and promote the recruitment of proteins that potentiate the transcriptional activity of LXRs (e.g. co-activators). This cell-free assay uses a recombinant fusion protein composed of the LXR LBD and a tag (e.g. GST, His, FLAG) that simplifies its purification, and a synthetic biotinylated peptide derived from the nuclear receptor interacting domain of a transcriptional co-activator protein, such as steroid receptor co-activator 1 (SRC-1). In one format, the tagged LBD fusion protein can be labeled using an antibody against the LBD tag coupled to europium (e.g. EU-labeled anti-GST antibody), and the co-activator peptide can be labeled with allophycocyanin (APC) coupled to streptavidin. In the presence of an agonist for LXR, the co-activator peptide is recruited to the LXR LBD, bringing the EU and APC moieties in close proximity. Upon excitation of the complex with light at 340nM, EU absorbs and transfers energy to the APC moiety resulting in emission at 665 nm. If there is no energy transfer (indicating lack of EU-APC proximity), EU emits at 615nm. Thus the ratio of the 665 to 615nm light emitted gives an indication of the strength of co-activator peptide recruitment, and thus of agonist binding to the LXR LBD.

[0094] Fusion proteins, amino acids 205-447 (Genbank NM_005693) for LXRα (NR1H3) and amino acids 203-461 (NM_007121for β) for LXRβ (NR1H3), were cloned in-frame at the Sal1 and Not1 sites of pGEX4T-3 (27-4583-03 Amersham Pharmacia Biotech). A biotinylated peptide sequence was derived from SRC-1 (amino acids 676 to 700): biotin-CPSSHSSLTERHKILHRLLQEGSPSC-OH.

[0095] A master mix is prepared (5nM GST-LXR-LBD, 5nM Biotinylated SRC-1 peptide, 10nM APC-Streptavidin (Prozyme Phycolink streptavidin APC, PJ25S), and 5n MEU-Anti-GST Antibody) in FRET buffer (50mM Tris pH 7.5, 50mM KCl 1mM DTT, 0.1% BSA). To each well of a 384 well plate, 20μL of this master mix is added. Final FRET reaction: 5nM fusion protein, 5nM SRC-1 peptide, 10nM APC-Streptavidin, 5nm EU-Anti-GST Antibody (PerkinElmer AD0064). Test compounds are diluted in half-log, 12-point serial dilutions in DMSO, starting at 1mM and 100nL of compound is transferred to the master mix for a final concentration of 5μM-28pM in the assay wells. Plates are incubated at room temperature for 3 hours and fluorescence resonance energy

transfer read. Results are expressed as the ratio of APC fluorescence to EU fluorescence times one thousand.

[0096] The ratio of 665nm to 615nm is multiplied by a factor of 1000 to simplify data analysis. DMSO values are subtracted from ratios to account for background. Data is visualized using XLfit3 and dose-response curves are fitted using a 4-parameter logistic model or sigmoidal single-site dose-response equation (equation 205 in XLfit3.05). EC50 is defined as the concentration at which the compound elicits a response that is half way between the maximum and minimum values. Relative efficacy (or percent efficacy) is calculated by comparison of the response elicited by the compound with the maximum value obtained for a reference LXR modulator.

[0097] Compounds of Formula I, in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, for example, as indicated by the *in vitro* tests described in this application. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

WE CLAIM:

1. A compound of Formula I:



in which

n is selected from 0, 1, 2 and 3;

Z is selected from C and S(O); each

Y is independently selected from $-CR_4=$ and $-N=$; wherein R_4 is selected from hydrogen, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

R_1 is selected from halo, cyano, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy and $-C(O)OR_4$; wherein R_4 is as described above;

R_2 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_2 is optionally substituted with 1 to 5 radicals independently selected from halo, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-C(O)NR_5R_5$, $-OR_5$, $-OC(O)R_5$, $-NR_5R_6$, $-C(O)R_5$ and $-NR_5C(O)R_5$; wherein R_5 and R_6 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, C_{6-10}aryl-C_{0-4}alkyl, C_{3-8}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-4}alkyl; or R_5 and R_6 together with the nitrogen atom to which R_5 and R_6 are attached form C_{5-10}heteroaryl or C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_5 or the combination of R_5 and R_6 is optionally substituted with 1 to 4 radicals independently

selected from halo, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl and halo-substituted-C_{1-6}alkoxy;

R_3 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_3 is substituted with 1 to 5 radicals independently selected from halo, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-OXR_7$, $-OXC(O)NR_7R_8$, $-OXC(O)NR_7XC(O)OR_8$, $-OXC(O)NR_7XOR_8$, $-OXC(O)NR_7XNR_7R_8$, $-OXC(O)NR_7XS(O)_{0-2}R_8$, $-OXC(O)NR_7XNR_7C(O)R_8$, $-OXC(O)NR_7XC(O)XC(O)OR_8$, $-OXC(O)NR_7R_9$, $-OXC(O)OR_7$, $-OXOR_7$, $-OXR_9$, $-XR_9$, $-OXC(O)R_9$, $-OXS(O)_{0-2}R_9$ and $-OXC(O)NR_7CR_7[C(O)R_8]_2$;wherein X is a selected from a bond and C_{1-6}alkylene wherein any methylene of X can optionally be replaced with a divalent radical selected from C(O), NR_7, $S(O)_2$ and O; R_7 and R_8 are independently selected from hydrogen, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{2-6}alkenyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; R_9 is selected from C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-4}alkyl; wherein any alkyl of R_9 can have a hydrogen replaced with $-C(O)OR_{10}$; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from halo, C_{1-6}alkyl, C_{3-12}cycloalkyl, halo-substituted-C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkoxy, $-XC(O)OR_{10}$, $-XC(O)R_{10}$, $-XC(O)NR_{10}R_{10}$, $-XS(O)_{0-2}NR_{10}R_{10}$ and $-XS(O)_{0-2}R_{10}$; wherein R_{10} is independently selected from hydrogen and C_{1-6}alkyl; and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof.

2. The compound of claim 1 of Formula Ia:



in which

n is selected from 1, 2 and 3;

Y is selected from –CH= and –N=;

R_1 is selected from halo, C_{1-6}alkyl, and –C(O)OR_4; wherein R_4 is selected from hydrogen and C_{1-6}alkyl;

R_2 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_2 is optionally substituted with 1 to 4 radicals independently selected from halo, hydroxy, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl and –OC(O)R_5; wherein R_5 is selected from hydrogen and C_{1-6}alkyl; and

R_3 is selected from the group consisting of C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-8}heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_3 is substituted with 1 to 5 radicals independently selected from halo, hydroxyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, -OXR_7, -OXC(O)NR_7R_8, -OXC(O)NR_7XC(O)OR_8, -OXC(O)NR_7XOR_8, -OXC(O)NR_7XNR_7R_8, -OXC(O)NR_7XS(O)$_{0-2}R_8$, -OXC(O)NR_7XNR_7C(O)R_8, -OXC(O)NR_7XC(O)XC(O)OR_8, -OXC(O)NR_7R_9, -OXC(O)OR_7, -OXOR_7, -OXR_9, -XR_9, -OXC(O)R_9 and -OXC(O)NR_7CR_7[C(O)R_8]$_2$;wherein X is a selected from a bond and C_{1-6}alkylene; R_7 and R_8 are independently selected from hydrogen, cyano, C_{1-6}alkyl, halo-substituted-C_{1-6}alkyl, C_{2-6}alkenyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; R_9 is selected from C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-4}alkyl; wherein any alkyl of R_9 can have a hydrogen replaced with –C(O)OR_{10}; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from halo, C_{1-6}alkyl, C_{3-12}cycloalkyl, halo-substituted-C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkoxy, -XC(O)OR_{10}, -XC(O)R_{10}, -XC(O)$NR_{10}R_{10}$, -XS(O)$_{0-2}NR_{10}R_{10}$ and -XS(O)$_{0-2}R_{10}$; wherein R_{10} is independently selected from hydrogen and C_{1-6}alkyl.

3. The compound of claim 2 in which

R_1 is selected from fluoro, chloro, methyl and -C(O)OCH_3; and

R_2 is selected from the group consisting of phenyl, cyclohexyl, cyclopentyl and pyridinyl; wherein any aryl, heteroaryl or cycloalkyl of R_2 is optionally substituted with

1 to 4 radicals independently selected from fluoro, chloro, bromo, hydroxy, methyl, methoxy, trifluoromethyl and $-OC(O)CH_3$.

4. The compound of claim 3 in which R_3 is selected from the group consisting of phenyl, benzo[1,3]dioxolyl, pyridinyl and benzooxazolyl; wherein any aryl or heteroaryl of R_3 is substituted with 1 to 5 radicals independently selected from fluoro, chloro, bromo, methoxy, hydroxyl, difluoromethoxy, $-OCH_2C(O)NH_2$, $-OCH_2C(O)OCH_3$, $-OCH_2C(O)NHCH_3$, $-OCH_2C(O)N(CH_3)_2$, $-R_9$, $-OR_9$, $-OCH_2R_9$, $-OCH_2C(O)R_9$, $-OCH_2C(O)NHR_9$, $-OCH_2C(O)N(CH_3)R_9$, $-OCH_2CN$, $-OCH_2C_2H_3$, $-OCH_2C_2H_4$, $-O(CH_2)_2OH$, $-OCH_2C(O)NH(CH_2)_2C(O)OC_2H_5$, $-OCH_2C(O)NH(CH_2)_2CH_2F$, $-OCH_2C(O)NH(CH_2)_2C(O)OH$, $-OCH_2C(O)NHC(O)(CH_2)_2C(O)OCH_3$, $-OCH_2C(O)NH(CH_2)_2NHC(O)CH_3$, $-OCH_2C(O)NHCH_2C(O)C_2H_5$, $-OCH_2C(O)NH(CH_2)_2C(O)OC_4H_9$, $-OCH_2C(O)NHCH_2C(O)OC_2H_5$, $-OCH_2C(O)NHCH[C(O)OC_2H_5]_2$, $-S(O)_2CH_3$, $-OCH_2C(O)NHCH_2CF_3$, $-OCH_2C(O)NHCH_2C(O)(CH_2)_2C(O)OCH_3$, $-OCH_2C(O)N(CH_3)CH_2C(O)OCH_3$, $-OCH_2C(O)NH(CH_2)_3OC_2H_5$, $-OCH_2C(O)NH(CH_2)_3OCH(CH_3)_2$, $-OCH_2C(O)NH(CH_2)_2SCH_3$, $-OCH_2C(O)NHCH_2CH(CH_3)_2$, $-OCH_2C(O)NHCH_2CH(CH_3)C_2H_5$, $-OCH_2C(O)NHCH(CH_3)C(O)OC_2H_5$, $-OCH_2C(O)NHCH_2CH(CH_3)_2$ and $-OCH_2C(O)(CH_2)_3OCH(CH_3)_2$;

wherein R_9 is phenyl, cyclopropyl-methyl, isoxazolyl, benzthiazolyl, furanyl, furanyl-methyl, pyridinyl, 4-oxo-4,5-dihydro-thiazol-2-yl, pyrazolyl, isothiazolyl, 1,3,4-thiadiazolyl, thiazolyl, phenethyl, morpholino, morpholino-propyl, isoxazolyl-methyl, pyrimidinyl, tetrahydro-pyranyl, 2-oxo-2,3-dihydro-pyrimidin-4-yl, piperazinyl, pyrrolyl, piperidinyl, pyrazinyl, imidazolyl, imidazolyl-propyl, benzo[1,3]dioxolyl, benzo[1,3]dioxolyl-propyl, 2-oxo-pyrrolidin-1-yl and 2-oxo-pyrrolidin-1-yl-propyl; wherein any alkyl of R_9 can have a hydrogen replaced with $-C(O)OC_2H_5$; wherein any aryl, heteroaryl or heterocycloalkyl of R_9 is optionally substituted with 1 to 4 radicals independently selected from methyl, ethyl, cyclopropyl, methoxy, trifluoromethyl, $-OC(O)CH_3$, -COOH, $-CH_2C(O)OH$, $-CH_2C(O)OC_2H_5$, $-CH_2C(O)OCH_3$, $-C(O)OCH_3$, $-C(O)NH_2$, $-C(O)NHCH_3$ and $-C(O)CH_3$.

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

6. A method for treating a disease or disorder in an animal in which modulation of LXR activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.

7. The method of claim 6 wherein the diseases or disorder are selected from cardiovascular disease, diabetes, neurodegenerative diseases and inflammation.

8. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease or disorder in an animal in which LXR activity contributes to the pathology and/or symptomology of the disease, said disease being selected from cardiovascular disease, diabetes, neurodegenerative diseases and inflammation.

COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS

ABSTRACT OF THE DISCLOSURE

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

Application Data Sheet

Application Information

Application number::	
Filing Date::	
Application Type::	Provisional
Subject Matter::	Utility
Suggested classification::	
Suggested Group Art Unit::	
CD-ROM or CD-R??::	
Number of CD disks::	
Number of copies of CDs::	
Sequence Submission::	
Computer Readable Form (CRF)?::	
Number of copies of CRF::	
Title::	COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS
Attorney Docket Number::	P1165US00
Request for Early Publication::	No
Request for Non-Publication::	
Suggested Drawing Figure::	
Total Drawing Sheets::	0
Small Entity?::	No
Latin name::	
Variety denomination name::	
Petition included?::	No
Petition Type::	
Licensed US Govt. Agency::	
Contract or Grant Numbers One::	
Secrecy Order in Parent Appl.::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	Italy
Status::	Full Capacity
Given Name::	Valentina
Middle Name::	
Family Name::	Molteni
Name Suffix::	
City of Residence::	San Diego
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	2475 E Street
City of Mailing Address::	San Diego
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92102

Applicant Authority Type::	Inventor
Primary Citizenship Country::	People's Republic of China
Status::	Full Capacity
Given Name::	Xiaolin
Middle Name::	
Family Name::	Li
Name Suffix::	
City of Residence::	Del Mar
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	14059-G Mango Drive
City of Mailing Address::	Del Mar
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92014

Applicant Authority Type::	Inventor
Primary Citizenship Country::	United States of America
Status::	Full Capacity
Given Name::	Juliet
Middle Name::	
Family Name::	Nabakka
Name Suffix::	
City of Residence::	San Diego
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	6120 Decena Drive #105
City of Mailing Address::	San Diego
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92120

Applicant Authority Type::	Inventor
Primary Citizenship Country::	United States of America
Status::	Full Capacity
Given Name::	David Archer
Middle Name::	
Family Name::	Ellis
Name Suffix::	
City of Residence::	San Diego
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	1631 State Street, #2
City of Mailing Address::	San Diego
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92101

Applicant Authority Type::	Inventor
Primary Citizenship Country::	United States of America
Status::	Full Capacity

Given Name::	Beth Marie
Middle Name::	
Family Name::	Anaclerio
Name Suffix::	
City of Residence::	San Diego
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	10721 Ballystock Court
City of Mailing Address::	San Diego
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92130

Applicant Authority Type::	Inventor
Primary Citizenship Country::	United States of America
Status::	Full Capacity
Given Name::	John
Middle Name::	
Family Name::	Wityak
Name Suffix::	
City of Residence::	Carlsbad
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	3377 Avenida Nieve
City of Mailing Address::	Carlsbad
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92009

Applicant Authority Type::	Inventor
Primary Citizenship Country::	Spain/United States of America
Status::	Full Capacity
Given Name::	Enrique
Middle Name::	

Family Name::	Saez
Name Suffix::	
City of Residence::	San Diego
State or Province of Residence::	California
Country of Residence::	US
Street of Mailing Address::	1547 ½ Felspar Street
City of Mailing Address::	San Diego
State or Province of Mailing Address::	California
Country of Mailing Address::	US
Postal or Zip Code of Mailing Address::	92109

Correspondence Information

Correspondence Customer Number::	29490

Representative Information

Representative Customer Number::	29490

Assignee Information

Assignee Name::	IRM LLC
Street of mailing address::	PO Box HM 2899
City of mailing address::	Hamilton
State or Province of mailing address::	
Country of mailing address::	Bermuda
Postal or Zip Code of mailing address::	HM LX